US20240041837A1 - Triazolone compounds and uses thereof - Google Patents

Triazolone compounds and uses thereof Download PDF

Info

Publication number
US20240041837A1
US20240041837A1 US18/304,815 US202318304815A US2024041837A1 US 20240041837 A1 US20240041837 A1 US 20240041837A1 US 202318304815 A US202318304815 A US 202318304815A US 2024041837 A1 US2024041837 A1 US 2024041837A1
Authority
US
United States
Prior art keywords
alkyl
cycloalkyl
mmol
butyl
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/304,815
Inventor
Nicholas Simon STOCK
Austin Chih-Yu Chen
Yalda Mostofi Bravo
Jason Duarte Jacintho
Jill Melissa Baccei
Brian Andrew Stearns
Ryan Christopher Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tempest Therapeutics Inc
Original Assignee
Tempest Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tempest Therapeutics Inc filed Critical Tempest Therapeutics Inc
Priority to US18/304,815 priority Critical patent/US20240041837A1/en
Assigned to TEMPEST THERAPEUTICS, INC. reassignment TEMPEST THERAPEUTICS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: INCEPTION 2, INC.
Assigned to INCEPTION 2, INC. reassignment INCEPTION 2, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INCEPTION SCIENCES, INC.
Assigned to INCEPTION SCIENCES, INC. reassignment INCEPTION SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BACCEI, JILL MELISSA, CLARK, RYAN CHRISTOPHER, BRAVO, YALDA MOSTOFI, CHEN, AUSTIN CHIH-YU, JACINTHO, JASON DUARTE, STEARNS, BRIAN ANDREW, STOCK, NICHOLAS SIMON
Publication of US20240041837A1 publication Critical patent/US20240041837A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • This invention is directed to novel triazolones, or pharmaceutically acceptable salts thereof, useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers.
  • the invention disclosed herein is further directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers comprising administration of selective PPAR ⁇ antagonists.
  • the compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.
  • PPAR ⁇ is known to be an important regulator of fatty acid oxidation. See Pyper, et al., Nucl. Recept. Signal 8:e002., e002 (2010). It has been reported that the expression of the PPAR ⁇ gene can be higher in human chronic lymphocyte leukemia (CLL) making this cancer type sensitive to therapies aimed at reducing FAO (Samudio et al., J. Clin. Invest. 120:142-156 (2010)). This effect may generalize to several cancer types.
  • CLL chronic lymphocyte leukemia
  • ovarian cancer and breast cancer (Linher-Melville et al., 2011, BMC, 4; 11:56), thrive in an adipose rich environment and as a result can be negatively impacted by targeted therapies tha reduce fatty acid metabolism (Nieman et al., 2011, Nat Med. 2011 Oct. 30:17(11):1498-503).
  • Still other cancers that rely on FAO include prostate cancer (Liu. Prostate Cancer Prostatic Dis, 2006; 9(3):230-4), colon cancer (Holla et al., 2011.
  • JCB 286(34):30003-30009 pancreatic cancer
  • pancreatic cancer Khasawneh et al., 2009, PNAS 106(9):3354-3359
  • lung cancer Zaugg el al., 2011, Genes and Development, 25:1041-1051.
  • GW6471 (Xu et al., Nature 415, 813-817 (2002) and MK-866 (Kehrer et al., Biochem. J, 356, 899-906 (2001) have been identified as antagonists of PPAR ⁇ .
  • MK-866 whose primary activity is as an inhibitor of FLAP, has been disclosed to induce apoptosis in a human chronic lymphocytic leukemia cell line in a FLAP-independent manner; and has also been disclosed to induce apoptosis in prostate and gliobl astoma cell lines.
  • antagonism of PPAR ⁇ by small molecules provides a panoply of anti-cancer treatment opportunities to: reduce or halt proliferation; decrease or reverse immunosupression; enhance apoptosis; and increase susceptibility of cancerous cells to other anti-cancer agents.
  • These cancers include prostate, breast, colon and pancreatic cancer, among others.
  • CML chronic myeloid leukemia
  • HSC hematopoietic stem cell
  • PPAR ⁇ antagonists have also been shown to inhibit HCV replication and thereby prove useful in the treatment of HCV infection (Rakic et al., Chem. & Biol. 13, 23-30 (January 2006)).
  • PPAR modulators have been shown to inhibit viral transcription and replication and thereby prove useful in the treatment of viral diseases (Capeau el al., PPAR Research Volume 2009, Article ID 393408, 2 pages).
  • PPAR ⁇ antagonists are useful in the treatment of HIV infection.
  • PPAR ⁇ antagonists have also been disclosed to be useful in the treatment of metabolic disorders (WO2012/027482A2). Metabolic disorders include, but are not limited to diabetes, obesity, metabolic syndrome, impaired glucose tolerance, syndrome X, and cardiovascular disease.
  • the invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof.
  • the invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukenia, melanoma and other cancers.
  • the invention disclosed herein is further directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers through the administration of a therapeutically effective amount of a selective PPARa, antagonist.
  • the compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.
  • FIG. 1 shows the ability of Example 6 to inhibit the metastasis of B16F10 melanoma cells to the lung.
  • the invention is directed to a compound of Formula I
  • A2a is phenyl or a 6 membered heteroaromatic ring having 1, 2 or 3 N in the heteroaromatic ring
  • A2b is a 5 membered heteroaromatic ring having 1, 2 or 3 heteroatoms independently selected from O. S and N;
  • R 1 and R 2 are each hydrogen.
  • R 3 is not hydrogen. In some embodiments, R 4 is not hydrogen. In some embodiments, R 3 is not hydrogen; and R 4 is not hydrogen.
  • the invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the invention is directed to a method of treating a cancer which is negatively impacted by diminution in its metabolism of fatty acid, through the administration of a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
  • cancer is selected from prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, and melanoma.
  • the invention is directed to a method of treating cancer involving the administration of a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
  • the invention is directed to a method of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers through the administration of a therapeutically effective amount of a compound according to Claim 1 , or a pharmaceutically acceptable salt thereof.
  • patient includes mammals such as mice, rats, cows, sheep, pigs, rabbits, goats, horses, monkeys, dogs, cats, and humans.
  • halo or halogen refers to any radical of fluorine, chlorine, bromine or iodine.
  • alkyl refers to a saturated hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms.
  • C 1-6 alkyl indicates that the group may have from 1 to 6 (inclusive) carbon atoms in it. Any atom can be optionally substituted, e.g., by one or more substitutents.
  • alkyl groups include without limitation methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl and tert-butyl.
  • haloalkyl refers to an alkyl group, in which at least one hydrogen atom is replaced by halo. In some embodiments, more than one hydrogen atom (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) are replaced by halo. In these embodiments, the hydrogen atoms can each be replaced by the same halogen (e.g., fluoro) or the hydrogen atoms can be replaced by a combination of different halogens (e.g., fluoro and chloro).
  • Haloalkyl also includes alkyl moieties in which all hydrogens have been replaced by halo (sometimes referred to herein as perhaloalkyl, e.g., perfluoroalkyl, such as trifluoromethyl). Any atom can be optionally substituted, e.g., by one or more substituents.
  • alkoxy refers to a group of formula —O(alkyl).
  • Alkoxy can be, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 2-pentoxy, 3-pentoxy, or hexyloxy.
  • thioalkoxy refers to a group of formula —S(alkyl).
  • haloalkoxy and halothioalkoxy refer to —O(haloalkyl) and —S(haloalkyl), respectively.
  • sulfhydryl refers to —SH.
  • aralkyl refers to an alkyl moiety in which an alkyl hydrogen atom is replaced by an aryl group. One of the carbons of the alkyl moiety serves as the point of attachment of the aralkyl group to another moiety. Any ring or chain atom can be optionally substituted e.g., by one or more substituents.
  • Non-limiting examples of“aralkyl” include benzyl, 2-phenylethyl, and 3-phenylpropyl groups.
  • alkenyl refers to a straight or branched hydrocarbon chain containing the indicated number of carbon atoms and having one or more carbon-carbon double bonds. Any atom can be optionally substituted, e.g., by one or more substituents. Alkenyl groups can include, e.g., vinyl, allyl, 1-butenyl, and 2-hexenyl.
  • heterocycle or “heterocyclic”, as used herein except where noted, represents a stable 4-, 5-, 6- or 7-membered monocyclic- or stable 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered fused bicyclic heterocyclic ring system which comprises at least one non-aromatic (i.e. saturated or partially unsaturated) ring which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and wherein the nitrogen heteroatom may optionally be quaternized.
  • non-aromatic i.e. saturated or partially unsaturated
  • the second ring may also be a non-aromatic ring which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, as defined above, or the second ring may be a benzene ring, or a “cycloalkyl”, or a “cycloalkenyl”, as defined immediately below.
  • heterocyclic groups include, but are not limited to, azetidine, chroman, dihydrofuran, dihydropyran, dioxane, dioxolane, hexahydroazepine, imidazolidine, imidazoline, indoline, isochroman, isoindoline, isothiazoline, isothiazolidine, isoxazoline, isoxazolidine, morpholine, oxazoline, oxazolidine, oxetane, piperazine, piperidine, pyran, pyrazolidine, pyrazoline, pyrrolidine, pyrroline, tetrahydrofuran, tetrahydropyran, thiamorpholine, thiazoline, thiazolidine, thiomorpholine and N-oxides thereof.
  • cycloalkyl refers to a fully saturated monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon groups. Any atom can be optionally substituted, e.g., by one or more substituents. A ring carbon serves as the point of attachment of a cycloalkyl group to another moiety. Cycloalkyl moieties can include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, and norbornyl (bicycle[2.2.1]heptyl).
  • cycloalkenyl refers to partially unsaturated monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon groups.
  • a ring carbon e.g., saturated or unsaturated is the point of attachment of the cycloalkenyl substituent. Any atom can be optionally substituted e.g., by one or more substituents.
  • Cycloalkenyl moieties can include, e.g., cyclopentenyl, cyclohexenyl, cyclohexadienyl, or norbornenyl.
  • cycloalkylene refers to a divalent monocyclic cycloalkyl group having the indicated number of ring atoms.
  • heterocycloalkylene refers to a divalent monocyclic heterocyclyl group having the indicated number of ring atoms.
  • aryl as used herein, is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl, or biphenyl.
  • heteroaryl represents a stable 5, 6 or 7-membered monocyclic- or stable 9 or 10-membered fused bicyclic ring system which comprises at least one aromatic ring, —which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • the second ring need not be aromatic and need not comprise a heteroatom.
  • heteroaryl includes, for example, a stable 5, 6 or 7-membered monocyclic aromatic ring consisting of carbon atoms and from one to four heteroatoms, as defined immediately above, fused to a benzene ring, or fused to a “heterocycle”, “cycloalkyl”, or a “cycloalkenyl”, as defined above.
  • heteroaryl groups include, but are not limited to, benzimidazole, benzisothiazole, benzisoxazole, benzofuran, isobenzofuran, benzothiazole, benzothiophene, benzotriazole, benzoxazole, carboline, cinnoline, furan, furazan, imidazole, indazole, indole, indolizine, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, phthalazine, pteridine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and N-oxides thereof.
  • acyl refers to those groups derived from an organic acid by removal of the hydroxy portion of the acid. Accordingly, acyl is meant to include, for example, acetyl, propionyl, butyryl, decanoyl, pivaloyl, benzoyl and the like.
  • the compounds of this invention may contain one or more stereocenters and thus occur as racemates and racemic mixtures, enantiomerically-enriched mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures.
  • the compounds of this invention may also be represented in multiple tautomeric forms, in such instances, the invention expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented. All such isomeric forms of such compounds are expressly included in the present invention.
  • the compounds of this invention include the compounds themselves, as well as their salts and their prodrugs, if applicable.
  • a salt for example, can be formed between an anion and a positively charged substituent (e.g., ammonium) on a compound described herein.
  • Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate.
  • asalt can also be formed between a cation and a negatively charged substituent (e.g., carboxylate) on a compound described herein.
  • Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion.
  • pharmaceutically acceptable salts refer to derivatives wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, bu t are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic,
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
  • the salts are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric, and tartaric acids.
  • salts may be prepared from pharmaceutically acceptable non-toxic bases, including inorganic and organic bases.
  • Such salts that may be prepared include a lithium salt, sodium salt, potassium salt, magnesium salt, calcium salt, dicyclohexylamine salt, N-methyl-D-glucamine salt, tris(hydroxymethyl)methylamine salt, arginine salt, lysine salt, and the like.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium, iodine-125 or carbon-14. All isotopic variations of the compounds of the invention, whether radioactive or not, are intended to be encompassed within the scope of the invention.
  • hydrogen atoms of the compounds described herein may be replaced with deuterium atoms.
  • compounds of Formula I are prepared as prodrugs.
  • Prodrugs are generally dng precursors that, following administration to a subject and subsequent absorption, are converted to an active, or a more active species via some process, such as conversion by a metabolic pathway.
  • Examples of prodrugs include C 1-6 alkyl esters of carboxylic acid groups, which, upon administration to a subject, are capable of providing active compounds.
  • pharmaceutically acceptable carrier refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, or a pharmaceutically acceptable salt thereof, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
  • composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • Such term in relation to pharmaceutical composition is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • compositions of the present invention encompass any composition made by admixing a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the present invention includes within its scope prodrugs of the compounds of this invention.
  • prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.
  • the terms “administration of” or “administering a” compound shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs,” ed. H. Bundgaard, Elsevier, 1985. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.
  • the amount administered depends on the compound formulation, rote of administration, etc, and is generally empirically determined in routine trials, and variations will necessarily occur depending on the target, the host, and the route of administration, etc.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1, 3, 10 or 30 to about 30, 100, 300 or 1000 mg, according to the particular application.
  • the total daily dosage may be divided and administered in portions during the day if desired.
  • the invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers.
  • the invention is directed to a method of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers.
  • the invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof.
  • the invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers.
  • the invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPAR ⁇ , antagonist.
  • the methods include administering to the subject an effective amount of a compound of Formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein.
  • a compound of Formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein in the preparation of, or for use as, a medicament for the treatment (e.g., controlling, alleviating, or slowing the progression of) or prevention (e.g., delaying the onset of or reducing the risk of developing) of one or more diseases, disorders, or conditions caused by, or associated with, prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers.
  • a salt e.g., a pharmaceutically acceptable salt
  • the invention is directed a method of treating a cancer which is negatively impacted by diminution in its metabolism via fatty acid oxidation, comprising administration of a therapeutically effective amount of a compound of Formula I (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt).
  • the invention is directed to a method of treating a cancer having a metabolism that is reliant on fatty acid oxidation, comprising administration of a therapeutically effective amount of a compound of Formula I (and/or a compound of any of the other formulae described herein), or a pharmaceutically acceptable salt thereof.
  • the compounds and compositions described herein can, for example, be administered orally, parenterally (e.g., subcutaneously, intracutaneously, intravenously, intramuscularly, intraarticularly, intraarterially, intrasynovially, intrasternally, intrathecally, intralesionally and by intracranial injection or infusion techniques), by inhalation spray, topically, rectally, nasally, buccally, vaginally, via an implanted reservoir, by injection, subdermally, intraperitoneally, transmucosally, or in an ophthalmic preparation, with a dosage ranging from about 0.01 mg/kg to about 1000 mg/kg, (e.g., from about 0.01 to about 100 mg/kg, from about 0.1 to about 100 mg/kg, from about 1 to about 100 mg/kg, from about 1 to about 10 mg/kg) every 4 to 120 hours, or according to the requirements of the particular drug.
  • parenterally e.g., subcutaneously, intracutaneously, intravenously, intramus
  • compositions are administered by oral administration or by injection.
  • the methods herein include the administration of an effective amount of compound or compound composition to achieve the desired or stated effect.
  • the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • Dosage forms include from about 0.05 milligrams to about 2,000 milligrams (e.g., from about 0.1 milligrams to about 1,000 milligrams, from about 0.1 milligrams to about 500 milligrams, from about 0.1 milligrams to about 250 milligrams, from about 0.1 milligrams to about 100 milligrams, from about 0.1 milligrams to about 50 milligrams, or from about 0.1 milligrams to about 25 milligrams) of a compound of Formula I (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein.
  • the dosage forms can further include a pharmaceutically acceptable carrier and/or an additional therapeutic agent.
  • the compounds of the invention may be co-administered with one or more additional anti-cancer agents.
  • the additional anti-cancer agents include, but are not limited to alkylating agents such as cyclophosphamide, chlorambucil, mecloreethamine, ifosfamide, or melphalan; antimetabolites such as methotrexate, cytarabine, fludarabine, 6-mercaptopurine, azathioprene, pyrimidines, or 5-fluorouracil; antimitotic agents such as vincristine, paclitaxel, vinorelbine or docetaxaxel; a topoisomerase inhibitors such as doxorubicin or irinotecan; platinum derivatives such as cisplatin, carboplatin or oxaliplatin; hormone therapeutics such as tamoxifen; aromatase inhibitors such as bicalutamide, anastrozole, exemestane or letrozo
  • anti-cancer agents for use in combination with the compounds include one or more of the following: abiraterone, adriamycin, dactinomycin, bleomycin, vinblastine, cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa, bicalutamide; bisantrenehydrochloride; bisnafidedimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; car
  • the additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention (e.g., sequentially, or on different overlapping schedules with the administration of one or more compounds of Formula (I) (and/or a compound of any of the other formulae including any subgenera or specific compounds thereof)).
  • these agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
  • these agents can be given as a separate dose that is administered at about the same time as one or more compounds of Formula (I) (and/or a compound of any of the other formulae including any subgenera or specific compounds thereof) are administered (e.g., simultaneously with the administration of one or more compounds of Formula (I) (and/or a compound of any of the other formulae including any subgenera or specific compounds thereof)).
  • compositions of this invention include a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent can be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
  • compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
  • pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • test compounds for agonist or antagonist activities against human PPAR ⁇ receptors was performed using a commercial kit, Human PPAR ⁇ Reporter Assay System (Indigo Biosciences, Cat. #1B00111).
  • This nuclear receptor assay system utilizes proprietary non-human mammalian cells engineered to provide constitutive, high-level expression of Human PPAR ⁇ . Because these cells incorporate a PPAR ⁇ -responsive luciferase reporter gene, quantifying expressed luciferase activity provides a sensitive surrogate measure of PPAR ⁇ activity in the treated cells.
  • the primary application of this reporter assay system is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against human PPAR ⁇ . While this assay may be used to measure agonism, each of the Examples, infra, exhibits antagonism rather than agonism. Briefly, the reporter cells are dispensed into wells of the assay plate and then immediately dosed with test compounds.
  • LDR Luciferase Detection Reagent
  • a Mouse PPAR ⁇ Reporter Assay System was used (Indigo Biosciences, Cat. #M00111). Activity of test compounds to antagonize or agonize other isoforms of human PPAR, for example ⁇ / ⁇ and ⁇ , were assessed using the corresponding kits from Indigo Biosciences (Cat. #IB00121 and #IB00101, respectively). In addition to PPAR activity, compounds were also screened for activity against other nuclear hormone receptors including Estrogen Receptor ⁇ , Glucocorticoid Receptor and Thyroid Receptor ⁇ using commercially available kits (Indigo Biosciences, Cat. #IB00411, IB00201 and IB01101, respectively).
  • Each assay system from Indigo Biosciences uses technology analogous to the human PPAR ⁇ kit, with the variance being that the cells used for each assay were engineered to over-express the receptor of interest.
  • the appropriate receptor agonist (included with each kit) was used at ⁇ EC80 for assays in which antagonist potency was being assessed.
  • PPAR PPAR PPAR Thyroid Gluco- Estrogen alpha beta/delta gamma Receptor corticoid Receptor IC 50 IC 50 ⁇ Receptor ⁇
  • Fatty acid oxidation is measured using 3 H palmitate metabolism into 3 H 2 O as described previously (Nieman et al., 2011). Briefly, cells (e g. HepG2, PC3 and CLL) are plated in growth media and allowed to adhere overnight. Cells are then treated with compound or 40 ⁇ M etomoxir (an inhibitor of fatty acid oxidation) as control. After treatment, cells are washed with DPBS followed by incubation in assay buffer (growth media, 3 H palmitate and compound). After incubation, media is collected and proteins precipitated with 5% tricholoroacetic acid. The precipitate is pelleted by centrifugation and the supernatant collected. Any remaining 3 H palmitate in the supernatant is then removed by purification over a Dowex anion exchange column. 3 H 2 O is then measured by scintillation counting.
  • etomoxir an inhibitor of fatty acid oxidation
  • CLL cells were cultured at 2 ⁇ 10 5 cells/200 ⁇ L of RPMI1640 supplemented with 10% FCS in 96-well plates under various treatment conditions. Determination of CLL cell viability was based on the analysis of mitochondrial transmembrane potential ( ⁇ m) using 3,3′-dihexylaxacarbocyanine iodide (DiOC6) (Invitrogen) and cell membrane permeability to propidium iodide (PI) (Sigma). For viability assays, 100 ⁇ L of the cell culture was collected at the indicated time points and transferred to polypropylene tubes containing 100 ⁇ L of 40 ⁇ M DiOC6 and 10 ⁇ g/mL PI in culture media. The cells were then incubated at 37° C. for 15 min and analyzed within 30 min by flow cytometry using an Accuri C6 flow cytometer. The percentage of viable cells was determined by gating on PI negative and DiOC6 bright cells.
  • DIOC6 3,3′-dihe
  • CD-1 mice were treated with test compound 1-2 hours prior to oral gavage with the PPAR alpha agonist WY14,643 (3 mg/kg).
  • animals were euthanized 6 hours after agonist treatment.
  • mice were dosed again with antagonist and WY14,643 on day 2 and day 3. In this case, mice were euthanized 6 hours following WY14,643 on day 3.
  • blood was collected for DMPK analysis. Liver was collected, placed into Trizol and stored at ⁇ 80° C. until processing.
  • RNA was extracted from thawed and homogenized tissue using standard Trizol RNA isolation methods. RT-PCR was performed on the extracted RNA using primers specific for PPAR alpha regulated genes. Quantitative PCR was performed on the resulting cDNA and expression was normalized to ⁇ -actin.
  • B16F10 cells were cultured in standard growth media, harvested when approximately 50% confluent and injected into C57BL/6 mice via the tail vein (50,000 cells per mouse in 200 ⁇ L). Mice were treated daily with test compound. On day 21, mice were euthanized. Lungs were harvested and placed into Fekete's solution overnight to facilitate visualization of the tumors. Black nodules were enumerated.
  • FIG. 1 shows inhibition of metastasis of B16F10 melanoma cells to the lung following oral doses of Example 6 at 0.3, 3 and 30 mg/kg.
  • Statistics were performed by ANOVA with Dunnett's Multiple Comparison Test post-hoc to determine statistical differences from vehicle treatment group. * denotes P ⁇ 0.05, while *** denotes P ⁇ 0.001.
  • the starting materials used for the synthesis are either synthesized or obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Fluka. Acros Organics, Alfa Aesar, VWR Scientific, and the like. General methods for the preparation of compounds can be modified by the use of appropriate reagents and conditions for the introduction of the various moieties found in the structures are provided herein.
  • compounds described herein are prepared as outlined in the following general synthetic scheme.
  • Step 1 To a solution of 3-bromobenzaldehyde (5.00 g, 27.0 mmol) in DMF (18 mL) was added sodium cyanide (331 mg, 6.8 mmol) and the resulting solution was heated at 45° C. for 30 min. A solution of acrylonitrile (1.55 mL, 23.7 mmol) in DMF (2 mL) was added dropwise over a period of 20 minutes and the heating continued for 3 hrs. The solution was allowed to cool after which AcOH (1 mL) was added, the reaction mixture partitioned between EtOAc and water, the organic phase extracted, dried (MgSO 4 ), filtered and evaporated in vacuo. The residue was purified using silica gel chromatography (0 to 30% EtOAc in hexanes) to afford 3.1 g of 4-(3-bromophenyl)-4-oxobutanenitile as a yellow oil.
  • Step 2 To a solution of the isolated nitrile (3.1 g, 13.0 mmol) in ethylene glycol (22 mL) was added water (0.5 mL), hydrazine monohydrate (1.5 mL) and potassium hydroxide (3.34 g). The reaction mixture was heated to 195° C. until analysis by LCMS indicated complete reaction, after which it was allowed to cool to room temperature, diluted with water and acidifed to pH ⁇ 2 with 2N HCl. The resulting solution was extracted with EtOAc, dried (MgSO 4 ), filtered and evaporated in vacuo. Purification of the residue on silica gel (0 to 30% acetone in hexanes) afforded 2.9 g of the title acid.
  • Step 1 The previously isolated 4-(3-bromophenyl)butanehydrazide (11.9 mmol) was dissolved in THF (50 mL) to which was added ethyl isocyanate (1.13 mL, 14.3 mmol). After stirring at room temperature for 12 hrs. the solution was evaporated to dryness to afford 2-(4-(3-bromophenyl)butanoyl)-N-ethylhydrazinecarboxamide which was then used without further purification.
  • Step 2 To a solution of the isolated carboxamide in MeOH (50 mL) was added KOH (6 g) and the reaction mixture was heated to reflux for 16 hrs. After complete reaction as judged by LCMS analysis, the solvent was removed and the residue diluted in DCM and acidified with 1N HCl with cooling. Extraction of the resulting mixture with DCM, drying of the organic phase (MgSO 4 ), filtration and evaporation of the filtrate in vacuo afforded crude 3-(3-(3-bromophenyl)propyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one which could be purified on silica gel (0 to 100% EtOAc in hexanes).
  • Step 1 To a solution of 5-bromo-2-methylphenol (1.5 g, 8.0 mmol) in DMF (10 mL) was added Cs 2 CO 3 (3.9 g, 12.0 mmol) followed by iodomethane (0.55 mL, 8.8 mmol). The resulting suspension was stirred vigorously for 24 hrs after which it was diluted with EtOAc and washed with water. The organic phase was dried (MgSO 4 ), filtered, evaporated in vacuo and the residue purified on silica gel (0 to 5% EtOAc gradient in hexanes) to afford 4-bromo-2-methoxy-1-methylbenzene as a colorless oil.
  • Step 2 To a solution of 4-bromo-2-methoxy-1-methylbenzene (1.2 g, 6.0 mmol) in CCl 4 (15 mL) was added N-bromosuccinimide (1.17 g, 6.5 mmol) and benzoyl peroxide (50 mg). The resulting mixture was heated under reflux for 6 hrs, allowed to cool, evaporated and the residue purified on silica gel eluting with a gradient of 0 to 10% EtOAc in hexanes. The isolated bromide (440 mg, 1.6 mmol) was then dissolved in DMF (2 mL) and potassium cyanide (204 mg, 3.1 mmol) added.
  • Step 1 In a 500 mL Parr shaker flask was dissolved (E)-tert-butyl 2-(4-(tert-butyl)benzylidene)hydrazine-carboxylate (15.0 g, 54.0 mmol, prepared according to the procedure described in Braden, T. M. et al., Org. Process Res. Dev. 2007, 11, 431-440) in iPrOH (75 mL) and EtOAc (25 mL). To this was then added Adam's catalyst (0.7 g, 0.3 mmol) and the resulting suspension was thoroughly deoxygenated via subsurface purging with nitrogen.
  • E E-tert-butyl 2-(4-(tert-butyl)benzylidene)hydrazine-carboxylate
  • the reaction vessel was then connected to a Parr shaker and the reaction suspension was shaken under 50 psi of H 2 for 3 days (or until no further consumption of hydrogen gas could be discerned). At this point, the excess H 2 was discharged from the vessel and the reaction was immediately quenched with DCM.
  • the deactivated catalyst was then removed via filtration through a pad of DCM-wetted celite and the insolubles were washed thoroughly with DCM. The filtrate thus obtained was concentrated in vacuo to furnish a colorless oil. This residue was then transferred as an iPrOH (100 mL) solution to a 500 mL Parr shaker flask and added another batch of Adam's catalyst (0.7 g, 0.3 mmol).
  • Step 2 In an oven-dried 1 L RBF equipped with a magnetic stirrer was dissolved tert-butyl 2-(4-(tert-butyl)benzyl)hydrazinecarboxylate (15.1 g, 54.0 mmdl) in anhydrous DCM (500 mL). To this was then added neat ethyl isocyanate (6.7 mL, 86 mmol) drop-wise over a period of 15 min and the resulting solution was allowed to stir under nitrogen at RT over 48 h.
  • Step 3 In an oven-dried 1 L RBF equipped with a magnetic stirrer was dissolved tert-butyl 2-(4-(tert-butyl)benzyl)-2-(ethylcarbamoyl)hydrazinecarboxylate (19.5 g, 54.0 mmol) in anhydrous DCM (500 mL). To this was then added neat MsOH (4.7 mL, 73 mmol) drop-wise over a period of 15 min and the resulting solution was allowed to stir under nitrogen at RT over 16 h. The volatiles were then in vacuo and the resulting residue was co-evaporated with DCM (3 ⁇ 500 mL) and MeOH (3 ⁇ 500 mL) to furnish 19.1 g (99% yield) of intermediate (M) as a pale yellow foam.
  • Example 1 2-(3′-(3-(1-(4-(tert-Butyl)benzyl) 4 -ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid
  • Step 1 To a solution of 3-(3-(3-bromophenyl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (250 mg, 0.55 mmol) in a mixture of DME (5 mL) and water (2 mL) was added potassium carbonate (191 mg, 1.38 mmol) and 3-ethoxycarbonylmethylphenylboronic acid (191 mg, 0.66 mmol). After sparging the mixture with nitrogen, Pd(PPh 3 ) 4 (30 mg, cat.) was added and the reaction heated at 85° C. for 3 hrs.
  • Step 2 To a solution of the aforementioned ester (200 mg, 0.37 mmol) in a mixture of THF (4 mL), MeOH (2 mL) and water (2 mL) was added lithium hydroxide monohydrate (100 mg, 2.4 mmol) and the reaction stirred at room temperature until complete ester hydrolysis was evident as determined by LCMS analysis. Solid citric acid was added to adjust pH to ⁇ 4 and the solution partitioned between EtOAc and water. The organic phase was extracted, dried (MgSO 4 ), filtered and evaporated to afford the title acid as a colorless solid.
  • Step 1 To a solution of 4-bromo-2-methylphenol (5.0 g, 26.7 mmol) in DMF (20 mL) was added Cs 2 CO 3 (13.0 g, 39.9 mmol) and iodoethane (2.6 mL, 32.5 mmol). The reaction was stirred vigorously for 24 hrs after which the suspension was partitioned between EtOAc and water, the organic phase extracted, wash with water, dried (MgSO 4 ), filtered and evaporated to afford 4-bromo-1-ethoxy-2-methylbenzene used without further purification.
  • Cs 2 CO 3 13.0 g, 39.9 mmol
  • iodoethane 2.6 mL, 32.5 mmol
  • Step 2 To a solution of 4-bromo-1-ethoxy-2-methylbenzene (5.0 g, 23.1 mmol) in CCl 4 (80 mL) was added N-bromosuccinimide (4.93 g, 27.6 mmol) and benzoyl peroxide (100 mg, cat.). The reaction mixture was then heated to reflux for a period of 3 hrs after which it was allowed to cool, partially evaporated then filtered to remove the succinimide. The filtrate was then evaporated to dryness to afford the benzylbromide which was used without further purification.
  • Step 3 To the crude 4-bromo-2-(bromomethyl)-1-ethoxybenzene (23.1 mmol) isolated previously was added DMF (20 mL) and potassium cyanide (2.26 g, 34.7 mmol) and the slurry stirred at room temperature for 48 hrs. The reaction mixture was partitioned between EtOAc and water, the organic phase separated, dried (MgSO 4 ), filtered and evaporated to afford a mixture of the mono and bis cyanomethyl derivatives. Purification of the mixture using silica gel chromatography (0 to 10% EtOAc in hexanes) afforded 2.5 g of 2-(5-bromo-2-ethoxyphenyl)acetonitrile.
  • Step 4 To 2-(5-bromo-2-ethoxyphenyl)acetonitrile (1.0 g, 4.16 mmol) in 2 mL of aqueous KOH (50%) was added tetrabutylammonium bromide (200 mg) and 1,2-dibromoethane (541 ⁇ L, 6.2 mmol) and heated in a sealed vial at 50° C. with vigorous stirring for 4 hrs. The mixture was partitioned between EtOAc and 1N HCl, the organic phase separated, dried (MgSO 4 ), filtered and evaporated in vacuo. The afforded 1-(5-bromo-2-ethoxyphenyl)cyclopropanecarbonitrile was used without further purification.
  • Example 5 was prepared analogously to example 1 using 1-(5-bromo-2-ethoxyphenyl)cyclopropanecarbonitrile as the coupling partner. Furthermore, hydrolysis of the resulting nitrile after cross-coupling was performed using KOH in ethylene glycol and water at 150° C.
  • Example 8 1-(3′-(3-(1-(4-(tert-Butyl)benzyl) 4 -ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-yl)cyclopropanecarboxylic acid
  • Step 1 To a solution of 3-(3-(3-bromophenyl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (300 mg, 0.6 mmol) in a mixture of DME (5.5 mL) and water (2.5 mL) was added potassium carbonate (250 mg, 1.80 mmol) and 3-amino-6-bromopyridine (135 mg, 0.78 mmol). After sparging the mixture with nitrogen, Pd(PPh 3 ) 4 (30 mg, cat.) was added and the reaction heated at 85° C. for 6 hrs.
  • Step 2 To a solution of the isolated 3-(3-(3-(5-aminopyridin-2-yl)phenyl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (50 mg, 0.106 mmol) in pyridine (0.8 mL) was added benzenesulfonyl chloride (14 ⁇ L, 0.106 mmol). After stirring for 48 hrs, the reaction mixture was diluted with EtOAc, washed with water, dried (MgSO 4 ), filtered and evaporated in vacuo. The isolated residue was purified on silica gel eluting with a gradient of 0 to 5% MeOH in CHCl 3 to afford the title compound.
  • Step 1 To a suspension of LiAlH 4 (0.75 g, 3.11 mmol) in diethyl ether (8 mL) at 0° C. was added a solution of methyl 5-bromo-2-methylbenzoate (949 mg, 4.14 mmol) in diethyl ether (2 mL) dropwise. The reaction mixture was allowed to slowly warm tort, then quenched with EtOAc, partitioned between EtOAc and 2N HCl and extracted (EtOAc). The organic phase was washed with water, dried (MgSO 4 ), filtered and evaporated in vacuo to afford the crude alcohol which can be used without further purification
  • Step 2 To the aforementioned alcohol (818 mg, 4.1 mmol) in diethyl ether (10 mL) cooled to 0° C. was added PBr 3 (0.2 ml, 2.07 mmol) and stirred at 0° C. for 1 hr. The reaction was then quenched with water, diluted with ether, washed with sodium bicarbonate solution, the organic phase separated and dried (MgSO 4 ), filtered and evaporated yielding 726 mg of the benzyl bromide.
  • PBr 3 0.2 ml, 2.07 mmol
  • Step 3 To 4-bromo-2-(bromomethyl)-1-methylbenzene (726 mg, 2.75 mmol) in DMF (8 mL) was added sodium cyanide (142 mg, 2.89 mmol) and the resulting suspension heated to 50° C. for 4 hrs. The reaction mixture was diluted with EtOAc, washed with water then brine, dried (MgSO 4 ), filtered and evaporated in vacuo. The isolated residue was purified on silica gel eluting with a gradient of 0 to 50% EtOAc in hexanes to afford 2-(5-bromo-2-methylphenyl)acetonitrile.
  • Step 4 1-(5-bromo-2-methylphenyl)cyclopropanecarbonitrile was then prepared analogously to the method described in Example 5, Step 4.
  • Example 14 was completed under the same conditions as described for Example 5.
  • Example 16 2-(3′-(3-(1-(4-(If-Butyl)benzyl)-ethyl-5-oxo-4,5-dihydro-H-1,2,4-triazol-3-yl)propyl)-4-(cyclopropylmethoxy)-[1,1′-biphenyl]-3-yl)acetic acid
  • Example 17 2-(3′-(3-(1-(4-(tert-Butyl)benzyl)-4ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl) 4 -fluoro-[1,1′-biphenyl]-3-yl)acetic acid
  • Example 18 2-(3′-(3-(1-(4-(tert-Butyl)benzyl) 4 -ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-6-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid
  • Example 20 N-((3′-(3-(1-(4-(tert-Butyl)benzyl) 4 -ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-YI)propyl)-[1,1′-biphenyl]-3-yl)methyl)benzenesulfonamide
  • Step 1 A mixture of 1-(4-(tert-butyl)benzyl)-4-ethyl-3-(3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1H-1,2,4-triazol-5(4H)-one (223 mg, 0.443 mmol), 3-bromobenzyl amine (98 mg, 0.532 mmol, 1.2 eq) and potassium carbonate (183 mg, 1.33 mmol, 3 eq) were taken up in DME (2 mL) and water (1 mL) solution.
  • Step 2 A mixture of 3-(3-(3′-(aminomethyl)-[1,1′-biphenyl]-3-yl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (35 mg, 0.0726 mmol) and benzene sulfonylchloride (10 ⁇ L, 0.0798 mmol, 1.1 eq) was stirred in pyridine (1 mL) at room temperature for 24 hr. The mixture was poured onto dichloromethane (40 mL) and washed with saturated CuSO 4 , water, and brine.
  • Step 1 To a solution of 4-(3-bromophenyl)-4-oxobutanenitrile (1.11 g, 4.66 mmol) in toluene (10 mL) was added Deoxyfluor (8.63 mL, 23.31 mmol, 2.7 M solution in Toluene) followed by EOH (0.16 m L, 2.80 mmol). The mixture was stirred at 80° C. for 16 hrs. The solution was cooled to rt and diluted with diethyl ether and a solution of saturated aqueous NaHCO 3 . The organic layer was separated and washed sequentially with saturated aqueous NaHCO 3 , 1M aqueous HCl, and water.
  • Step 2 4-(3-Bromophenyl)-4,4-difluorobutanenitrile (0.57 g, 2.19 mmol), ethylene glycol (20 mL), water (2 mL), and KOH (0.701 g, 17.53 mmol) were combined and heated at 80° C. for 16 hrs. The solution was cooled to rt, diluted with EtOAc and quenched with 1M aqueous HCl. The organics were separated and washed sequentially with 0.1M aqueous HCl and brine, filtered through a Na 2 SO 4 /paper plug and concentrated.
  • Step 3 4-(3-Bromophenyl)-4,4-difluorobutanoic acid (0.20 g, 0.717 mmol), Hunig's base (0.33 mL, 1.86 mmol) and 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.327 g, 0.86 mmol) were combined in anhydrous DMF (7 mL). The reaction solution was stirred for 40 min at rt, then intermediate (M) (0.248 g, 0.717 mmol) was added. The resulting solution was allowed to stir at rt for 16 h.
  • intermediate (M) 0.248 g, 0.717 mmol
  • Step 4 To an EtOAc solution (8 mL) of 2-(4-(3-bromophenyl)-4,4-difluorobutanoyl)-1-(4-(tert-butyl)benzyl)-N-ethylhydrazinecarboxamide (0.365 g, 0.717 mmol) was added camphorsulfonic acid (0.18 g, 0.717 mmol) and the resulting solution was heated at reflux for 16 h. The reaction mixture was then diluted with EtOAc and 1 N aq. HCl. The organics were washed sequentially with 1M NaOH and water, and then concentrated.
  • Step 5 Under a nitrogen atmosphere, 3-(3-(3-bromophenyl)-3,3-difluoropropyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (0.040 g, 0.081 mmol) and methyl 2-(2-ethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate (0.029 g, 0.089 mmol) were dissolved in dioxane (3 mL) to which was then added a solution of saturated aqueous NaHCO 3 (1 mL).
  • Step 6 To a solution of methyl 2-(3′-(3-(1-(4-(tert-butyl)benzyl) 4 -ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1,1-difluoropropyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetate (0.029 g, 0.048 mmol) in THF (1 mL) and MeOH (1 mL) was added water (0.62 mL) and 1M aq. LiOH (0.38 mL, 0.37 mmol). The resulting mixture was then stirred at 35° C. for 48 hrs.
  • Step 1 3-(3-(3-Bromophenyl)-3,3-difluoropropyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (0.110 g, 0.223 mmol), bis(pinacolato)diborane (0.074 g, 0.290 mmol), KOAc (0.066 g, 0.669 mmol) were dissolved in dioxane (4 mL) and the resulting solution was subsurface purged with N 2 for 5 minutes after which, Pd(dppf)Cl 2 (0.016 g, 0.014 mmol) was added.
  • the resulting mixture was stirred in a sealed pressure vessel at 85° C. for 16 hrs.
  • the solution was cooled to rt and diluted with DCM and water.
  • the organics were washed once more with water and the solution was filtered through a Na 2 SO 4 /paper plug and concentrated.
  • Step 2 Under a nitrogen atmosphere, 1-(4-(tert-butyl)benzyl)-3-(3,3-difluoro-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (0.065 g, 0.120 mmol) from the previous step and N-(6-bromopyridin-3-yl)benzenesulfonamide (0.042 g, 0.133 mmol) were dissolved in dioxane (3 mL).
  • Step 1 To a degassed (sparged) solution of 2-bromo-6-chloropyridine (2.0 g, 10.4 mmol) in THF (75 mL) was added Pd(PPh 3 ) 4 (200 mg) followed by a solution of (4-ethoxy-4-oxobutyl)zinc(II) bromide (0.5M in THF: 20.8 mL, 20.8 mmol). After stirring at room temperature for 2 hrs, the solution was poured on to a mixture of ice and 1N HCl, extracted with EtOAc, the organic phase separated, dried (MgSO 4 ), filtered and evaporated. The isolated residue was purified on silica gel (0 to 30% EtOAc in hexanes) to afford 1.4 g of ethyl 4-(6-chloropyridin-2-yl)butanoate.
  • Step 2 Lithium hydroxide monohydrate (400 mg) was added to a solution of ethyl 4-(6-chloropyridin-2-yl)butanoate (1.4 g, 7.0 mmol) in a mixture of THF (20 mL), MeOH (8 mL) and water (8 mL). After stirring at room temperature for 1 hr, the solution was diluted with EtOAc and water. Sol id citric acid was then added until an acidic pH was attained and the organic phase separated, washed with water, dried (MgSO 4 ), filtered and evaporated to afford 4-(6-chloropyridin-2-yl)butanoic acid. The crude product thus obtained was used without further purification.
  • Step 3 To a solution of 4-(6-chloropyridin-2-yl)butanoic acid (600 mg, 3.0 mmol) in DMF (15 mL) was added HATU (1.3 g, 3.42 mmol) followed by DIPEA (1.6 mL) and stirred at RT for 30 minutes. Intermediate (M) (1.2 g, 3.47 mmol) was then added and the solution allowed to stir at rt for 24 hrs. The reaction mixture was partitioned between EtOAc and water, the organic phase separated, dried (MgSO 4 ) and filtered. To the filtrate was then added camphorsulfonic acid (697 mg, 3.0 mmol) and the resulting mixture was heated to reflux for 24 hrs.
  • HATU 1.3 g, 3.42 mmol
  • DIPEA 1.6 mL
  • Step 4 The title compound was then obtained as previously described for Example 1, whereby the requisite boronate was cross-coupled and the resulting ester was then hydrolyzed under the same conditions.
  • Example 25 3-(3-(3′-(1H-Tetrazol-5-yl)-[1,1′-biphenyl]-3-yl)propyl)-1-(4-(ter-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one
  • Step 1 To a THF solution of 2,4-dichloropyrimidine (1.00 g, 6.71 mmol) was added at 0° C. (4-ethoxy-4-oxobutyl)zinc(II) bromide (13.42 mL, 6.71 mmol, 0.5 M in THF) followed by Pd(PPh) 4 (0.194 g, 0.167 mmol). The reaction mixture thus obtained was then allowed to slowly warm to rt. By TLC, it was noted that this reaction had stalled after 1.5 hr, so another spatula tip of Pd(PPh) 4 was then added and reaction was allowed to continue at rt for another 16 hrs.
  • Step 2 Under a nitrogen atmosphere, ethyl 4-(2-chloropyrimidin-4-yl)butanoate (0.193 g, 0.842 mmol) and ethyl 2-(2-ethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetonitrile (0.220 g, 0.766 mmol) were dissolved in dioxane (8 mL) to which was added a solution of saturated aqueous NaHCO 3 (4 mL). The resulting solution was then subsurface purged with N 2 for 5 minutes after which, Pd(PPh) 4 (0.088 g, 0.077 mmol) was added.
  • Pd(PPh) 4 0.088 g, 0.077 mmol
  • Step 3 To a solution of ethyl 4-(2-(3-(cyanomethyl) 4 -ethoxyphenyl)pyrimidin-4-yl)butanoate (0.360 g, 1.02 mmol) in THF (8 mL) and MeOH (8 mL) was added 1M aq. LiOH (8.02 mL, 8.02 mmol). The resulting mixture was then stirred at rt for 1.5 hrs. The solvents were evaporated and the residue treated with EtOAc and a 20% aq. solution of citric acid. The organic layer was separated and washed with water (2 ⁇ ). The organics were then filtered through a Na 2 SO 4 /paper plug and concentrated. The resulting crude 4-(2-(3-(cyanomethyl)-4-ethoxyphenyl)pyrimidin-4-yl)butanoic acid thus obtained was used directly in the next step.
  • Step 4 4-(2-(3-(Cyanomethyl)-4-ethoxyphenyl)pyrimidin-4-yl)butanoic acid (0.32 g, 0.984 mmol), Hunig's base (0.45 mL, 1.86 mmol) and 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.449 g, 1.18 mmol) were combined in anhydrous DMF (10 mL). The reaction solution was stirred for 40 min at rt before intermediate (M) (0.248 g, 0.717 mmol), dissolved in a minimal amount of DMF, was added dropwise.
  • M intermediate
  • Step 5 To an EtOAc solution (10 mL) of 1-(4-(tert-butyl)benzyl)-2-(4-(2-(3-(cyanomethyl)-4-ethoxyphenyl)pyrimidin-4-yl)butanoyl)-N-ethylhydrazinecarboxamide (0.547 g, 0.982 mmol) was added camphorsulfonic acid (0.228 g, 0.982 mmol) and the resulting solution was heated at reflux for 16 h. The reaction mixture was then diluted with EtOAc and brine. The organics were separated and washed sequentially with 1M NaOH, water, and brine. The organic extract was then dried over sodium sulfate, filtered and the filtrate concentrated.
  • Step 6 To a solution of 2-(5-(4-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyrimidin-2-yl)-2-ethoxyphenyl)acetonitrile (0.100 g, 0.186 mmol) in ethylene glycol (6 mL) and water (1.5 mL) was added 18M KOH (0.104 mL, 1.86 mmol). The resulting mixture was then stirred at 120° C. for 16 hrs. The reaction was quenched with 1 M aq.
  • Step 1 In a 75 mL screw-cap reaction flask equipped with a magnetic stirrer was combined 1-(4-(tert-butyl)benzyl)-4-ethyl-3-(3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1H-1,2,4-triazol-5(4H)-one (300 mg, 0.60 mmol), methyl 2-(benzyloxy)-5-bromobenzoate (200 mg, 0.60 mmol) and K 3 PO 4 (330 mg, 2.4 mmol) in DME (4 mL) and water (2 mL).
  • the resulting biphasic mixture was then subsurface purged with N 2 for 15 min after which, Pd 2 (dba) 3 (14 mg, 0.015 mmol) and 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (25 mg, 0.060 mmol) were added in one rapid portion.
  • the now golden-yellow biphasic suspension was subsurface purged with N 2 for another 15 min before the vessel was tightly sealed and then heated at 85° C. for 15 h.
  • the now dark orange reaction suspension was allowed to cool to RT, diluted with tert-butyl methyl ether and washed sequentially with 10% aq. HCl, water and brine.
  • Step 2 In a 500 mL Parr shaker flask was dissolved methyl 2-(3-(benzyloxy)-3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-yl)acetate (190 mg, 29 mmol) from the previous step in MeOH (10 mL). To this was then added Pd/C (10% wt/wt wet, 120 mg, 0.06 mmol) and the resulting suspension was thoroughly deoxygenated via subsurface purging with nitrogen.
  • the reaction vessel was then connected to a Parr shaker and the reaction suspension was shaken under 50 psi of H 2 for 5 h.
  • the excess H 2 was discharged from the vessel and the reaction was immediately quenched with DCM.
  • the deactivated catalyst was then removed via filtration through a pad of DCM-wetted celite and the insolubles were washed thoroughly with DCM. The filtrate thus obtained was concentrated in vacuo to furnish a pale yellow solid.
  • Step 3 In a 50 mL RBF equipped with a magnetic stirrer was added methyl 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-hydroxy-[1,1′-biphenyl]-4-yl)acetate (35 mg, 0.065 mmol) from the previous step in THF (1 mL) and MeOH (0.5 mL). To this was then added 2N aq. LiOH (0.2 mL, 0.4 mmol) and the resulting solution was stirred at RT for 16 h.

Abstract

The invention disclosed herein is directed to compounds of Formula Iand pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. Application Ser. No. 16/722,773, filed Dec. 20, 2019, which is a continuation of U.S. application Ser. No. 15/590,766, filed on May 9, 2017, now issued as U.S. Pat. No. 10,568,871 on Feb. 25, 2020, which is a continuation of U.S. application Ser. No. 14/654,225, filed on Jun. 19, 2015, now issued as U.S. Pat. No. 9,676,754 on Jun. 13, 2017, which is a U.S. National Stage Entry of International Application No. PCT/US2013/074197, filed on Dec. 10, 2013, which claims the benefit of U.S. Provisional Application No. 61/739,906, filed Dec. 20, 2012, the contents of each are incorporated herein by reference in their entireties.
    • FIELD OF THE INVENTION
  • This invention is directed to novel triazolones, or pharmaceutically acceptable salts thereof, useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers comprising administration of selective PPARα antagonists. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.
    • BACKGROUND OF THE INVENTION
  • While tremendous strides have been made in the treatment of various cancers, in many cases, cancer treatment continues to be a matter of administering one or more anti-cancer agents that are marginally less chemotoxic to healthy cells than they are to the cancer in question. In recognition of this problem, there has been substantial research effort aimed at identifying, understanding and taking advantage of phenotypical behavior peculiar to certain cancer cells. It has long been observed that most cancer cell types generate energy for cellular processes through aerobic glycolysis rather than through oxidative phosphorylation as found in the normal cell. This process, which became known as the “Warburg effect”, is highly energy inefficient and requires cancer cell mitochondria to resort to glucose fermentation to make up the energy deficit. Since perhaps the mid-1990's researchers have sought to identify methods of treating cancer that take advantage of the “Warburg effect” and associated aspects of cancer cell mitochondrial metabolism. See, for example, Wang, et al., Small mitochondrial-targeting molecules as anti-cancer agents, Mol. Aspects Med. 2010 February; 31(1): 75-92.
  • Samudio, et al., J. Clin. Invest. 120: 142-156 (2010), disclosed that in certain leukemia cell lines “mitochondrial uncoupling—the continuing reduction of oxygen without ATP synthesis—has recently been shown in leukemic cells to circumvent the ability of oxygen to inhibit glycolysis, and may promote the metabolic preference for glycolysis by shifting from pyruvate oxidation to fatty acid oxidation (FAO).” Samudio, et. al., also provided data indicating that inhibition of FAO could sensitize human leukemia cells to apoptosis, and further that inhibition of FAO may prove useful in the treatment of leukemia.
  • PPARα is known to be an important regulator of fatty acid oxidation. See Pyper, et al., Nucl. Recept. Signal 8:e002., e002 (2010). It has been reported that the expression of the PPARα gene can be higher in human chronic lymphocyte leukemia (CLL) making this cancer type sensitive to therapies aimed at reducing FAO (Samudio et al., J. Clin. Invest. 120:142-156 (2010)). This effect may generalize to several cancer types. For example, ovarian cancer and breast cancer (Linher-Melville et al., 2011, BMC, 4; 11:56), thrive in an adipose rich environment and as a result can be negatively impacted by targeted therapies tha reduce fatty acid metabolism (Nieman et al., 2011, Nat Med. 2011 Oct. 30:17(11):1498-503). Still other cancers that rely on FAO include prostate cancer (Liu. Prostate Cancer Prostatic Dis, 2006; 9(3):230-4), colon cancer (Holla et al., 2011. JCB 286(34):30003-30009), pancreatic cancer (Khasawneh et al., 2009, PNAS 106(9):3354-3359) and lung cancer (Zaugg el al., 2011, Genes and Development, 25:1041-1051).
  • GW6471 (Xu et al., Nature 415, 813-817 (2002) and MK-866 (Kehrer et al., Biochem. J, 356, 899-906 (2001) have been identified as antagonists of PPARα. Moreover, MK-866, whose primary activity is as an inhibitor of FLAP, has been disclosed to induce apoptosis in a human chronic lymphocytic leukemia cell line in a FLAP-independent manner; and has also been disclosed to induce apoptosis in prostate and gliobl astoma cell lines.
  • It is our belief that in cancers that rely heavily on FAO, antagonism of PPARα by small molecules provides a panoply of anti-cancer treatment opportunities to: reduce or halt proliferation; decrease or reverse immunosupression; enhance apoptosis; and increase susceptibility of cancerous cells to other anti-cancer agents. These cancers include prostate, breast, colon and pancreatic cancer, among others.
  • Chronic myeloid leukemia (CML) is model of hematopoietic stem cell (HSC) disease. In 2008, Ito et al. disclosed evidence linking the loss of promyelocytic leukemia (PML) gene expression with favorable outcomes in CML (Nature, 2008 Jun. 19; 453 (7198) 1072-1078). More recently Ito et al, disclosed that in the PML pathway, loss of PPARS and accompanying inhibition of mitochondrial FAO induced loss of hematopoietic stem cell (HSC) maintenance (Nature Medicine, doi:10.1038/nm.2882). Moreover, Carracedo et al. disclosed that whereas PML expression allowed luminal filling in 3D basement membrane breast cancer, the effect was reversed by inhibition of FAO (J. Clin. Invest. 2012:122(9):3088-3100). This and other evidence supports our view that inhibition of fatty acid oxidation, via antagonism of PPAR's (including PPARa), will prove effective in inhibiting asymmetric leukemia stem cell differentiation, and therefore, prove effective in preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers.
  • PPARα antagonists have also been shown to inhibit HCV replication and thereby prove useful in the treatment of HCV infection (Rakic et al., Chem. & Biol. 13, 23-30 (January 2006)). In some embodiments, PPAR modulators have been shown to inhibit viral transcription and replication and thereby prove useful in the treatment of viral diseases (Capeau el al., PPAR Research Volume 2009, Article ID 393408, 2 pages). In some embodiments, PPARα antagonists are useful in the treatment of HIV infection. PPARα antagonists have also been disclosed to be useful in the treatment of metabolic disorders (WO2012/027482A2). Metabolic disorders include, but are not limited to diabetes, obesity, metabolic syndrome, impaired glucose tolerance, syndrome X, and cardiovascular disease.
    • SUMMARY OF THE INVENTION
  • The invention disclosed herein is directed to compounds of Formula I
  • Figure US20240041837A1-20240208-C00002
  • and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukenia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers through the administration of a therapeutically effective amount of a selective PPARa, antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the ability of Example 6 to inhibit the metastasis of B16F10 melanoma cells to the lung.
    •  INCORPORATION BY REFERENCE
  • All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
    • DETAILED DESCRIPTION OF THE INVENTION
  • In one aspect the invention is directed to a compound of Formula I
  • Figure US20240041837A1-20240208-C00003
  • or a pharmaceutical acceptable salt thereof wherein:
      • A1 is phenyl or a 6-membered heteroaromatic ring having 1, 2 or 3 N in the heteroaromatic ring
      • A2 is selected from A2a or A2b
  • Figure US20240041837A1-20240208-C00004
  • wherein A2a is phenyl or a 6 membered heteroaromatic ring having 1, 2 or 3 N in the heteroaromatic ring, and A2b is a 5 membered heteroaromatic ring having 1, 2 or 3 heteroatoms independently selected from O. S and N;
      • X is selected from the group consisting of —(CH2)m—, —(CH2)m—O—(CH2)n—, —(CH2)m—NH—(CH2)n—, —(CH2)m—S(═O)o—(CH2)n—, optionally mono- or di-substituted with halogen, wherein m and n are independently 0, 1, 2, 3 or 4, and each o is independently 0, 1 or 2;
      • Y is O or S;
      • R1 and R2 are each independently selected from the group consisting of:
        • (a) hydrogen,
        • (b) halogen,
        • (c) CN,
        • (d) CF3,
        • (e) —C1-6alkyl,
        • (f) —C1-6alkyl-C(═O)OH,
        • (g) —O—(R′).
        • (h) —S(═O)oR7,
        • (i) —N(R7)(R8),
        • (j) —N(R7)—C(═O)—(R8),
        • (k) —N(R7)—C(═O)—O—(R8),
        • (l) —N(R7)S(═O)2(R8),
        • (m) —C3-6cycloalkyl,
        • (n) —C(═O)(R7),
        • (o) aryl,
        • (p) heteroaryl,
        • (q) —OC(═O)N(R7)(R8),
        • (r) —S(═O)2N(R7)(R8),
        • (s) —C(═O)N(R7)(R8), and
        • (t) —C(R7)(R8)OH,
          wherein the alkyl portion of choices (e) and (f), and the cycloalkyl portion of choice (m) are optionally substituted with halogen, and
          wherein the aryl of choice (o) and the heteroaryl of choice (p) are optionally mono- or di-substituted with substituents selected from halogen, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C1-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)˜C3-6cycloalkyl, and CN;
      • R3 is selected from the group consisting of:
        • (a) hydrogen,
        • (b) halogen,
        • (c) CN,
        • (d) CF3,
        • (e) —C1-6alkyl,
        • (f) —C1-6alkyl-C(═O)OH,
        • (g) —O—(R7),
        • (h) —S(═O)oR7,
        • (i) —N(R7)(R8),
        • (j) —N(R7)—C(═O)—(R8),
        • (k) —N(R7)—C(═O)—O—(R8),
        • (l) —N(R7)S(═O)2(R8),
        • (m) —C3-6cycloalkyl,
        • (n) —C(═O)(R7),
        • (o) aryl,
        • (p) heteroaryl,
        • (q) —OC(═O)N(R7)(R8),
        • (r) —S(═O)2N(R7)(R8),
        • (s) —C(═O)N(R7)(R8),
        • (t) —C(R7)(R8)OH,
        • (u) —NHC(═O)—N(R7)(R8),
        • (v) —C3-6cycloalkyl-COOH,
        • (w) heterocycle, and
        • (x) —C1-6alkylC(═O)—N(R7)(R8),
          wherein the alkyl portion of choices (e), (f) and (x), and the cycloalkyl portion of choices (in) and (v) are optionally substituted with halogen or hydroxyl, and
          wherein the aryl of choice (o), the heteroaryl of choice (p), and the heterocycle of choice (w) are optionally mono- or di-substituted with substituents selected from halogen, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C1-6cycloalkoxy, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)C3-4cycloalkyl, hydroxyl and CN:
      • R4 and R4′ are each independently selected from the group consisting of:
        • (a) hydrogen,
        • (b) —N(R7)(RA),
        • (c) —N(R7)S(═O)2R8,
        • (d) —N(R7)—C(═O)R8,
        • (e) —N(R7)C(═O)OR,
        • (f) —S(═O)oR7,
        • (g) —S(═O)2N(R7)(R8),
        • (h) —C(═O)R7,
        • (i) —C(═O)N(R7)(R8),
        • (j) —OC(═O)N(R7)(R8),
        • (k) —O—R7,
        • (l) —C(R7)(R8)OH,
        • (m) —C1-4alkyl-C(═O)NHS(═O)2R7,
        • (n) —C1-4alkyl-S(═O)2NHC(═O)R7,
        • (o) —C1-4alkyl-C(═O)—N(R7)(R8),
        • (p) —C1-4alkyl-N(R′)C(═O)(R8),
        • (q) —C1-4alkyl-N(R′)S(═O)2(R8),
        • (r) —C1-4alkyl-S(═O)2N(R7)(R8),
        • (s) —C1-4alkyl-N(R7)C(═O)O(R8)
        • (x) —C1-4alkyl-O—C(═O)N(R7)(R8)
        • (y) —C1-4alkyl-C(═O)(R7),
        • (v) —C1-4alkyl-C(R7)(R8)OH,
        • (w) —C1-4alkyl-O(R7),
        • (x) —C1-6alkyl-C(═O)OH,
        • (y) —C2-6alkenyl-C(═O)OH,
        • (z) —C3-6cycloalkyl-C(═O)OH,
        • (aa) —C3-6cycloalkyl-C(═O)NHS(═O)2R7,
        • (bb) —C3-6cycloalkyl-S(═O)2NHC(═O)R7,
        • (cc) —C3-6cycloalkyl-C(═O)—N(R7)(R8),
        • (dd) —C3-6cycloalkyl-N(R7)C(═O)(R8),
        • (ee) —C3-6cycloalkyl-N(R7)S(═O)2(R8),
        • (ff) —C3-6cycloalkyl-S(═O)2N(R7)(R8),
        • (gg) —C3-6cycloalkyl-N(R7)C(═O)O(R8),
        • (hh) —C3-6cycloalkyl-O—C(═O)N(R7)(R8),
        • (ii) —C1-6cycloalkyl-C(═O)(R7),
        • (jj) —C3-6cycloalkyl-C(R7)(R8)OH,
        • (kk) —C3-6cycloalkyl-O(R7),
        • (ll) —C(═O)OH,
        • (mm) aryl,
        • (nn) heteroaryl,
        • (oo) —C(═O)N(R7)S(═O)2(R8),
        • (pp) —S(═O)2N(R7)C(═O)(R8),
        • (qq) —NHS(═O)2N(R7)(R8),
        • (rr) —NHC(═O)N(R7)(R8),
        • (ss) —CH(OH)—C(═O)—N(R7)R8).
        • (tt) —C(═O)—C(═O)—N(R7)(R8),
        • (uu) —C3-6cycloalkyl,
        • (vv) —CF3,
        • (ww) —C1-6alkyl N(R7)R8),
        • (xx) -heterocycle,
        • (yy) —C1-6alkyl,
        • (zz) halogen, and
        • (aaa) —O—C1-6alkyl-N(R7)(R8),
          wherein the alkyl portion of choices (m), (n), (o), (p). (q), (r), (s), (t), (u), (v), (w), (x), (ww), (yy) and (aaa), the alkenyl portion of choice (y), and the cycloalkyl portion of choices (z), (aa), (bb), (cc), (dd), (ee), (ff), (gg), (hh), (ii), (jj), (kk) and (uu), are optionally mono- or di-substituted with halogen, CN, aryl, C1-6alkyl, halo C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, or C3-6cycloalkoxy, and
          wherein the aryl of choice (mm), the heteroaryl of choice (nn), and the heterocycle of choice (xx) are optionally mono- or di-substituted with substituents selected from halogen, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC3-6cycloalkyl, hydroxyl and CN, or
          wherein R3 and R4 or R4 and R4′ are joined together to form a 5- or 6-membered heterocyclic ring, said ring having one heteroatom selected from O and N, wherein said ring is optionally substituted with —C(═O)OH, or —C1-6alkyl-C(═O)OH, with the proviso that at least one of R3, R4 and R4′ is other than hydrogen;
      • R5 is selected from the group consisting of:
        • (a) hydrogen,
        • (b) —C1-6alkyl,
        • (c) —C1-4alkyl(R7),
        • (d) aryl,
        • (e)heteroaryl,
        • (f) —C3-6cycloalkyl,
        • (g) —C3-6cycloalkyl(R7),
        • (h) —C3-6cycloalkyl-O(R7),
        • (i) —C1-4alkyl-C3-6cycloalkyl,
        • (j) —C1-6alkoxy, and
        • (k) —C1-6cycloalkoxy,
          wherein the alkyl portion of choices (b), (c), (i) and (j) the cycloalkyl portion of choices (f), (g), (h), (i) and (k) are optionally substituted with halogen or C1-4alkyl, and
          wherein the aryl of choice (d) and the heteroaryl of choice (e), are optionally mono- or di-substituted with substituents selected from halogen, nitro, C1-6alkyl, CF3, C1-6alkoxy, halo C1-6alkyl, aryl, heteroaryl, C3-6cycloalkyl, C3-6cycloalkoxy, and CN;
      • R6 is selected from the group consisting of:
        • (a) hydrogen,
        • (b) —C1-6alkyl,
        • (c) —C1-6alkylaryl,
        • (d) —C1-6alkylheteroaryl,
        • (e) —S(═O)oC1-6alkyl(R7),
        • (g) —C3-6cycloalkyl,
        • (h) aryl,
        • (i) heteroaryl,
        • (j) —C(═O)C3-6cycloalkyl(R7),
        • (k) —S(═O)oC3-6cycloalkyl(R7), and
        • (l) —C1-6alkyl(R7),
          wherein the alkyl portion of choices (b), (c), (d), (e), (f), and (l) and the cycloalkyl portion of choices (g), (j), and (k), are optionally substituted with halogen or C1-4alkyl, and
          wherein the aryl portion of choices (c) and (h), and the heteroaryl portion of choices (d) and (i), are optionally mono- or di-substituted with substituents selected from halogen, nitro, —CF3, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, S(═O)oC3-6 cycloalkyl, and CN;
      • R7 and R8 are each independently selected from the following:
        • (a) hydrogen,
        • (b) —C1-6alkyl,
        • (c) —C3-6cycloalkyl,
        • (d) -aryl,
        • (e) -heteroaryl,
        • (f) —C1-6alkylaryl,
        • (g) —C1-6alkylheteroaryl,
        • (h) —C(═O)C1-6alkyl,
        • (i) —S(═O)o-aryl,
        • (j) —C1-6alkyl-C3-6cycloalkyl, and
        • (k) CF3,
          wherein the alkyl of choices (b), (f), (g), (h), and (j), and the cycloalkyl of choices (c) and (j), are each optionally mono-, di- or tri-substituted with halogen, and wherein the aryl portion of choices (d), (f) and (i), and the heteroaryl portion of choices (e) and (g), are each optionally mono- or di-substituted with substituents selected from halogen, —C(═O)OH, —CF3, —NHC(═O)CH3, nitro. C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-3alkyl), —NH(C3-6cycloalkyl), —N(C1-3alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-4alkyl, S(═O)oC3-6cycloalkyl, aryl, heteroaryl, hydroxyl, and CN;
      • R9 and R10 are each independently selected from the following
        • (a) hydrogen,
        • (b) —C1-6alkyl,
        • (c) —C3-6cycloalkyl,
        • (d) halogen,
        • (e) —OC3-cycloalkyl,
        • (f) CF3, and
        • (g) —C1-6alkoxy,
          wherein the alkyl portion of choice (b) and the cycloalkyl portion of choices (c) and (e), are each optionally mono-, di- or tri-substituted with halogen. In the alternative, choice (g) of R9 and R10 may also be mono-, di- or tri-substituted with halogen.
  • Within this aspect there is a genus wherein:
      • X is selected from the group consisting of —(CH2)m—, and —(CH2)m—O—(CH2)n—, optionally mono- or di-substituted with halogen, where m+n is 2, 3 or 4.
  • Within this genus there is a sub-genus wherein:
      • X is selected from —CH2CH2CH2—, or —CF2CH2CH2—.
  • Within this aspect there is an alternative genus wherein:
      • X is selected from the group consisting of —(CH2)m—, and —(CH2)m—O—(CH2)n—, optionally mono- or di-substituted with halogen, where m+n is 1, 2, 3 or 4.
  • Within this alternative genus there is a sub-genus wherein:
      • X is selected from —CH2CH2CH2—, —CF2CH2CH2—, or —OCH2—.
  • Within this aspect there is a genus wherein:
      • A1 is a substituted phenyl or substituted pyridine.
  • Within this genus there is a sub-genus wherein:
      • A2 is A2a.
  • Within this sub-genus there is a class wherein:
      • A2a is a substituted phenyl, substituted pyrimidine, substituted pyrazine, or substituted pyridine.
  • Within this aspect these is a genus wherein:
      • Y is O.
  • Within this aspect there is a genus wherein:
      • R1 and R2 are each independently selected from the group consisting of:
        • (a) hydrogen,
        • (b) halogen,
        • (c) CN,
        • (d) CF3,
        • (e) —C1-6alkyl,
        • (f) —O—(R7),
        • (g) —C3-6cycloalkyl, and
        • (h) —N(R′)(R8),
          wherein the alkyl portion of choice (e) and the cycloalkyl portion of choice (g) are optionally substituted with halogen.
  • Within this genus there is a sub-genus wherein:
      • R1 and R2 are each independently selected from:
        • (a) hydrogen.
        • (b) halogen,
        • (c) CF3,
        • (d) —C1-6alkyl, and
        • (e) —O—(R7),
          wherein the alkyl portion of choice (d) is optionally substituted with halogen.
  • Within this sub-genus there is a class wherein R1 and R2 are each hydrogen.
  • Within this aspect there is a genus wherein:
      • R3 is selected from the group consisting of:
        • (a) hydrogen,
        • (b) halogen,
        • (c) CF3,
        • (d) —C1-6alkyl,
        • (e) —O—(R7),
        • (f) —S(═O)oR7,
        • (g) —C3-6cycloalkyl,
        • (h) aryl,
        • (i) heteroaryl,
        • (j) —S(═O)2N(R7)(R8),
        • (k) —C(R7)(R8)OH,
        • (l) heterocycle, and
        • (m) —N(R7)S(═O)2(R8),
          wherein the alkyl portion of choice (d) and the cycloalkyl portion of choice (g) are optionally substituted with halogen or hydroxyl, and
          wherein the aryl of choice (h), the heteroaryl of choice (i), and the heterocycle of choice (1) are optionally mono- or di-substituted with substituents selected from halogen, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC3-6cycloalkyl, hydroxyl and CN.
  • Within this genus there is a sub-genus wherein:
      • R3 is selected from the group consisting of:
        • (a) hydrogen,
        • (b) —O—(R7),
        • (c) —N(R7)S(═O)2(R8), and
        • (d) —C1-6alkyl,
          wherein the alkyl portion of choice (d) is optionally substituted with halogen or hydroxyl.
  • Within this aspect there is a genus wherein:
      • R4 and R4′ are each independently selected from the group consisting of:
        • (a) hydrogen,
        • (b) —N(R7)S(═O)2R8,
        • (c) —N(R7)—C(═O)R8,
        • (d) —S(═O)oR7,
        • (e) —S(═O)2N(R7)(R8),
        • (f) —C(═O)N(R7)(R8),
        • (g) —O—(R7),
        • (h) —C(R7)(R8)OH,
        • (i) —C1-4alkyl-C(═O)NHS(═O)2R7,
        • (j) —C1-4alkyl-S(═O)2NHC(═O)R7,
        • (k) —C1-4alkyl-C(═O)—N(R7)(R8),
        • (l) —C1-4alkyl-N(R7)C(═O)(R8),
        • (m) —C1-4-alkyl-N(R7)S(═O)2(R8),
        • (n) —C1-4alkyl-S(═O)2N(R7)(R8),
        • (o) —C1-4alkyl-C(R7)(R8)OH,
        • (p) —C1-4alkyl-O(R7),
        • (q) —C1-6alkyl-C(O)OH,
        • (r) —C2-6alkenyl-C(═O)OH,
        • (s) —C3-6cycloalkyl-C(═O)OH.
        • (t) —C3-6cycloalkyl-C(═O)NHS(═O)2R7,
        • (u) —C3-6cycloalkyl-S(═O)2NHC(═O)R7,
        • (v) —C3-6cycloalkyl-C(═O)—N(R7)(R8),
        • (w) —C3-6cycloalkyl-N(R7)S(═O)2(R8),
        • (x) —C3-6cycloalkyl-S(═O)2N(R7)(R8),
        • (y) —C3-6cycloalkyl-N(R7)C(═O)O(R8),
        • (z) —C3-6cycloalkyl-C(R7)(R8)OH,
        • (aa) —C3-6cycloalkyl-O(R7),
        • (bb) —C(═O)OH,
        • (cc) aryl,
        • (dd) heteroaryl,
        • (ee) —C(═O)N(R7)S(═O)2(R8),
        • (ff) —S(═O)2N(R7)C(═O)(R8),
        • (gg) —NHS(═O)2N(R7)R8).
        • (hh) —NHC(═O)N(R7)(R8).
        • (ii) —C3-6cycloalkyl,
        • (j) CF3,
        • (kk) heterocycle,
        • (l1) —C1-6alkyl, and
        • (mm) halogen,
          wherein the alkyl portion of choices (i), (j), (k), (l), (m), (n), (o), (p), (q), and (ll), the alkenyl portion of choice (r), and the cycloalkyl portion of choices (s), (t), (u), (v), (w), (x), (y), (z), and (aa) are optionally mono- or di-substituted with halogen, CN, aryl, C1-4alkyl, halo C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, or C3-6cycloalkoxy and,
          wherein the aryl of choice (cc), the heteroaryl of choice (dd), and the heterocycle of choice (kk) are optionally mono- or di-substituted with substituents selected from halogen, hydroxyl, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC3-6cycloalkyl, and CN. In the alternative, choice (ii) of R4 and R4′ may also be mono- or di-substituted with halogen, CN, aryl, C1-6alkyl, halo C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, or C3-6cycloalkoxy halogen.
  • Within this genus there is a sub-genus wherein:
      • R4 and R4′ are each independently selected from the group consisting of:
        • (a) hydrogen,
        • (b) —N(R7)S(═O)2R8,
        • (c) —N(R7)—C(═O)R8,
        • (d) —O—(R7),
        • (e) —C(R7)(R8)OH,
        • (f) —C1-4alkyl-S(═O)2NHC(O)R7,
        • (g) —C1-4alkyl-N(R7)S(═O)2(R8),
        • (h) —C1-4alkyl-S(═O)2N(R7)(R8),
        • (i) —C1-4alkyl-O(R7),
        • (j) —C1-6alkyl-C(═O)OH,
        • (k) —C3-6cycloalkyl-C(═O)OH,
        • (l) —C3-6cycloalkyl-N(R7)S(═O)2(R8),
        • (m) —C3-6cycloalkyl-S(═O)2N(R7)(R8),
        • (n) —C3-6cycloalkyl-O(R7)
        • (o) —C(═O)OH,
        • (p) —C(═O)N(R7)S(═O)2(R8),
        • (q) —S(═O)2N(R7)C(═O)(R8),
        • (r) —NHS(═O)2N(R7)(R8),
        • (s) —C3-6cycloalkyl,
        • (t) CF3,
        • (u) heterocycle,
        • (v) —C1-6alkyl, and
        • (w) halogen,
          wherein the alkyl portion of choices (f), (g), (h), (i), (j) and (v), and the cycloalkyl portion of choices (k), (l), (m), (n), and (s), are optionally mono- or di-substituted with halogen, CN, aryl, C1-6alkyl, halo C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, or C3-6cycloalkoxy, and
          wherein the heterocycle of choice (u) is optionally mono- or di-substituted with substituents selected from halogen, hydroxyl, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC3-6cycloalkyl and CN.
  • Within this sub-genus there is class wherein:
      • R4 and R4′ are each independently selected from the group consisting of:
        • (a) —C(R7)(R8)OH,
        • (b) —N(R7)S(═O)2R8,
        • (c) —O—(R7),
        • (d) —C1-6alkyl-C(═O)OH,
        • (e) —C(═O)OH,
        • (f) —NHS(═O)2N(R7)(R8),
        • (g) —C3-6cycloalkyl,
        • (h) CF3,
        • (i) heterocycle,
        • (j) —C1-6alkyl, and
        • (k) halogen,
          wherein the alkyl portion of choices (d) and (j), and the cycloalkyl portion of choice (g) are optionally mono- or di-substituted with halogen. CN, aryl, C1-6alkyl, halo C1-6alkyl, C3-6cycloalkyl. C1-6alkoxy, or C3-6cycloalkoxy, and
          wherein the heterocycle of choice (i) is optionally mono- or di-substituted with substituents selected from halogen, hydroxyl, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C1-6cycloalkoxy, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC3-6cycloalkyl, and CN.
  • Within this aspect there is a genus wherein:
      • R3 is selected from the group consisting of:
        • (a) hydrogen,
        • (b) —C1-6alkyl,
        • (c) —C1-4alkyl(R7),
        • (d) aryl,
        • (e) heteroaryl,
        • (f) —C3-6cycloalkyl, and
        • (g) —C1-4alkyl-C3-4cycloalkyl,
          wherein the alkyl portion of choices (b), (c), and (g), the cycloalkyl portion of choices (f) and (g), are optionally substituted with halogen or C1-4alkyl, and
          wherein the aryl of choice (d) and the heteroaryl of choice (e), is optionally mono- or di-substituted with substituents selected from halogen, nitro, C1-6alkyl, CF3, C1-6alkoxy, halo C1-6alkyl, aryl, heteroaryl, C3-6cycloalkyl, C3-6cycloalkoxy, and CN.
  • Within this genus there is a sub-genus wherein
      • R5 is selected from the group consisting of:
        • (a) hydrogen,
        • (b) —C1-6alkyl, and
        • (c) —C1-4alkyl(R7),
          wherein the alkyl portion of choices (b) and (c) is optionally substituted with halogen or C1-4alkyl.
  • Within this aspect there is a genus wherein:
      • R6 is selected from the group consisting of:
        • (a) —C1-6alkylaryl,
        • (b) —C1-6alkylheteroaryl,
        • (c) —C3-6cycloalkyl,
        • (d) aryl,
        • (e) heteroaryl, and
        • (f) —C1-6alkyl(R7),
          wherein the alkyl portion of choices (a), (b) and (f), and the cycloalkyl portion of choice (c) are optionally substituted with halogen or C1-4alkyl, and
          wherein the aryl portion of choices (a) and (d), and the heteroaryl portion of choices (b) and (e), are optionally mono- or di-substituted with substituents selected from halogen, nitro. CF3, C1-6alkyl, C1-6alkoxy, halo C1-6 alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC3-6cycloalkyl, and CN.
  • Within this genus there is a sub-genus wherein:
      • R6 is selected from the group consisting of:
        • (a) —C1-6alkylaryl,
        • (b) —C1-6alkylheteroaryl, and
        • (c) —C1-6alkyl(R7),
          wherein the alkyl portion of choices (a), (b), and (c) is optionally substituted with halogen or C1-4alkyl, and
          wherein the aryl portion of choice (a), and the heteroaryl portion of choice (b), are optionally mono- or di-substituted with substituents selected from halogen, nitro, CF3, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, —NH(C1-falkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC3-6cycloalkyl, and CN.
  • Within this aspect there is a genus wherein:
      • R7 and R8 are each independently selected from the following:
        • (a) hydrogen,
        • (b) —C1-6alkyl,
        • (c) —C3-6cycloalkyl,
        • (d) aryl,
        • (e)heteroaryl, and
        • (f) CF3,
          wherein the alkyl of choice (b) and the cycloalkyl of choice (c) are optionally mono-, di- or tri-substituted with halogen, and
          wherein the aryl of choice (d) and the heteroaryl of choice (e) are optionally mono- or di-substituted with substituents selected from halogen, —C(═O)OH, CF3, —NHC(═O)—CH3, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-3alkyl), —NH(C3-6cycloalkyl), —N(C1-3alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-4alkyl, —S(═O)oC3-6cycloalkyl, aryl, heteroaryl, hydroxyl, and CN.
  • Within this aspect there is a genus wherein:
      • R9 and R10 are each independently
        • (a) hydrogen,
        • (b) —C1-6alkyl,
        • (c) halogen,
        • (d) CF3, and
        • (e) —C1-6alkoxy,
          wherein the alkyl of choice (b) is optionally mono-, di- or tri-substituted with halogen. In the alternative, the alkyl portion of choice (e) of R9 and R10 may also be mono-, di- or tri-substituted with halogen.
  • Within this aspect there is a genus wherein:
      • X is selected from the group consisting of —(CH2)m—, and —(CH2)m—O—(CH2)n—, optionally mono or di-substituted with halogen, where m+n is 2, 3 or 4;
      • Y is O;
      • A1 is a substituted phenyl or substituted pyridine;
      • A2 is A2a,
      • R1 and R2 are each independently selected from the group consisting of:
        • (a) hydrogen,
        • (b) halogen,
        • (c) CN,
        • (d) CF3,
        • (e) —C1-6alkyl,
        • (f) —O—(R7),
        • (g) —C3-6cycloalkyl, and
        • (h) —N(R7)(R8),
          wherein the alkyl portion of choice (e) and the cycloalkyl portion of choice (g) are optionally substituted with halogen;
      • R3 is selected from the group consisting of:
        • (a) hydrogen,
        • (b) halogen.
        • (c) CF3,
        • (d) —C1-6alkyl,
        • (e) —O—(R7),
        • (f) —S(═O)oR7,
        • (g) —C3-6cycloalkyl,
        • (h) aryl,
        • (i) heteroaryl,
        • (j) —S(═O)2N(R7)(R8),
        • (k) —C(R7)(R8)OH,
        • (l) heterocycle, and
        • (m) —N(R7)S(═O)2(R8),
          wherein the alkyl portion of choice (d) and the cycloalkyl portion of choice (g) are optionally substituted with halogen or hydroxyl, and
          wherein the aryl of choice (h), the heteroaryl of choice (i), and the heterocycle of choice (l) are optionally mono- or di-substituted with substituents selected from halogen, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC3-6cycloalkyl, hydroxyl and CN:
      • R4 and R4′ are each independently selected from the group consisting of:
        • (a) hydrogen,
        • (b) —N(R7)S(═O)R8,
        • (c) —N(R7)—C(═O)R8,
        • (d) —S(═O)oR7,
        • (e) —S(═O)2N(R7)(R8),
        • (f) —C(═O)N(R7)(R8),
        • (g) —O—(R7),
        • (h) —C(R7)(R8)OH,
        • (i) —C1-4alkyl-C(═O)NHS(═O)R7,
        • (j) —C1-4alkyl-S(═O % NHC(═O)R7,
        • (k) —C1-4alkyl-C(═O)—N(R7)(R8),
        • (l) —C1-4alkyl-N(R7)C(═O)(R8),
        • (m) —C1-4alkyl-N(R7)S(═O)(R8)
        • (n) —C1-4alkyl-S(═O)2N(R7)(R8),
        • (o) —C1-4alkyl-C(R7)(R8)OH,
        • (p) —C1-4alkyl-O(R7),
        • (q) —C1-6alkyl-C(═O)OH,
        • (r) —C2-6alkenyl-C(═O)OH,
        • (s) —C3-6cycloalkyl-C(═O)OH,
        • (t) —C3-6cycloalkyl-C(═O)NHS(═O)2R7,
        • (u) —C3-6cycloalkyl-S(═O)2NHC(═O)R7,
        • (v) —C3-6cycloalkyl-C(═O)—N(R7)(R8),
        • (w) —C3-6cycloalkyl-N(R7)S(═O)2(R8),
        • (x) —C3-6Cycloalkyl-S(═O)2N(R7)R8),
        • (y) —C3-6cycloalkyl-N(R7)C(═O)O(R8),
        • (z) —C3-6cycloalkyl-C(R7)(R8)OH,
        • (aa) —C3-6cycloalkyl-O(R7),
        • (bb) —C(═O)OH,
        • (cc) aryl,
        • (dd) heteroaryl,
        • (ee) —C(═O)N(R7)S(═O)2(R8),
        • (ff) —S(═O)2N(R7)C(═O)(R8),
        • (gg) —NHS(═O)2N(R7)(R8),
        • (hh) —NHC(═O)N(R7)(R8)
        • (ii) —C3-6cycloalkyl,
        • (jj) CF3,
        • (kk) heterocycle,
        • (ll) —C1-6alkyl, and
        • (mm) halogen,
          wherein the alkyl portion of choices (i), (j). (k), (l), (m), (n), (o), (p), (q), and (ll), the alkenyl portion of choice (r), and the cycloalkyl portion of choices (s), (t), (u), (v), (w), (x), (y), (z), and (aa) are optionally mono- or di-substituted with halogen, CN, aryl, C1-6alkyl, halo C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, or C3-6cycloalkoxy and,
          wherein the aryl of choice (cc), the heteroaryl of choice (dd), and the heterocycle of choice (kk) are optionally mono- or di-substituted with substituents selected from halogen, hydroxyl, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C1-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC3-6cycloalkyl, and CN;
      • R5 is selected from the group consisting of:
        • (a) hydrogen,
        • (b) —C1-6alkyl,
        • (c) —C1-4alkyl(R7),
        • (d) aryl,
        • (e) heteroaryl,
        • (f) —C3-6cycloalkyl, and
        • (g) —C1-4alkyl-C3-6cycloalkyl,
          wherein the alkyl portion of choices (b), (c) and (g), the cycloalkyl portion of choices (f) and (g), are optionally substituted with halogen or C1-4alkyl, and
          wherein the aryl of choice (d) and the heteroaryl of choice (e), are optionally mono- or di-substituted with substituents selected from halogen, nitro, C1-6alkyl, CF3, C1-6alkoxy, halo C1-6alkyl, aryl, heteroaryl, C3-6cycloalkyl, C3-6cycloalkoxy, and CN;
      • R6 is selected from the group consisting of:
        • (a) —C1-6alkylaryl,
        • (b) —C1-6alkylheteroaryl,
        • (c) C3-6cycloalkyl,
        • (d) aryl,
        • (e) heteroaryl, and
        • (f) —C1-6alkyl(R7),
          wherein the alkyl portion of choices (a), (b) and (f), and the cycloalkyl portion of choice (c) are optionally substituted with halogen or C1-4alkyl, and
          wherein the aryl portion of choices (a) and (d), and the heteroaryl portion of choices (b) and (e), are optionally mono- or di-substituted with substituents selected from halogen, nitro, CF3, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC3-6cycloalkyl, and CN;
      • R7 and R8 are each independently selected from the following:
        • (a) hydrogen,
        • (b) C1-6alkyl,
        • (c) C3-6cycloalkyl,
        • (d) aryl,
        • (e)heteroaryl, and
        • (f) CF3,
          wherein the alkyl of choice (b) and the cycloalkyl of choice (c) are optionally mono-, di- or tri-substituted with halo, and
          wherein the aryl of choice (d) and the heteroaryl of choice (e) are optionally mono- or di-substituted with substituents selected from halogen, —C(═O)OH, CF3, —NHC(═O)—CH3, nitro, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-3alkyl), —NH(C3-6cycloalkyl), —N(C1-3alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-4alkyl, —S(═O)oC3-6cycloalkyl, aryl, heteroaryl, hydroxyl, and CN;
          and
      • R9 and R10 are each independently
        • (a) hydrogen,
        • (b) —C1-6alkyl,
        • (c) halogen,
        • (d) CF3, and
        • (e) C1-6alkoxy,
          wherein the alkyl of choice (b) is optionally mono-, di- or tri-substituted with halogen. In the alternative aspect, choice (ii) of R4 and R4′ may also be mono- or di-substituted with halogen, CN, aryl, C1-6alkyl, halo C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, or C3-6cycloalkoxy halogen; and the alkyl portion of choice (e) is optionally mono-, di- or tri-substituted with halogen and choice (e) of R9 and R10 may also be mono-, di- or tri-substituted with halogen
  • Within this genus there is a sub-genus wherein:
      • A2 is A2a, and A2a is a substituted phenyl, substituted pyrimidine, substituted pyrazine, or substituted pyridine;
      • R1 and R2 are each independently selected from:
        • (a) hydrogen,
        • (b) halogen,
        • (c) CF3,
        • (d) C1-6alkyl, and
        • (e) —O—(R7),
          wherein the alkyl portion of choice (d) is optionally substituted with halogen;
      • R3 is selected from the group consisting of:
        • (a) hydrogen,
        • (b) —O—(R7),
        • (c) —N(R7)S(═O)(R8), and
        • (d) —C1-6alkyl,
          wherein the alkyl portion of choice (d) is optionally substituted with halogen or hydroxyl;
      • R4 and R4′ are each independently selected from the group consisting of:
        • (a) hydrogen,
        • (b) —N(R7)S(═O)R8,
        • (c) —N(R7)—C(═O)R8,
        • (d) —O—(R7),
        • (e) —C(R7)(R8)OH,
        • (f) —C1-4alkyl-S(═O)2NHC(═O)R7,
        • (g) —C1-4alkyl-N(R′)S(═O)2(R8),
        • (h) —C1-4alkyl-S(═O)2N(R7)(R8),
        • (i) —C1-4alkyl-O(R7),
        • (j) —C1-6alkyl-C(═O)OH,
        • (k) —C3-6cycloalkyl-C(═O)OH,
        • (l) —C3-6cycloalky-N(R7)S(═O)2(R8),
        • (m) —C3-6cycloalkyl-S(═O)2N(R7)(R8),
        • (n) —C3-6cycloalkyl-O(R7),
        • (o) —C(═O)OH,
        • (p) —C(═O)N(R7)S(═O)2(R8),
        • (q) —S(═O)2N(R7)C(═O)(R8),
        • (r) —NHS(═O)2N(R7)(R8),
        • (s) —C3-6cycloalkyl,
        • (t) CF3,
        • (u) heterocycle,
        • (v) —C1-6alkyl, and
        • (w) halogen,
          wherein the alkyl portion of choices (f), (g), (h), (i), (j), and (v), and the cycloalkyl portion of choices (k), (l), (m), (n), and (s), are optionally mono- or di-substituted with halogen, CN, aryl, C1-6alkyl, halo C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, or C3-6cycloalkoxy, and
          wherein the heterocycle of choice (u) is optionally mono- or di-substituted with substituents selected from halogen, hydroxyl, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-6alkyl), —NH(C3-6cycloalkyl). —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2. —S(═O)oC1-6akyl, —S(═O)oC3-6cycloalkyl and CN;
      • R5 is selected from the group consisting of:
        • (a) hydrogen,
        • (b) —C1-6alkyl, and
        • (c) —C1-4alkyl(R7),
          wherein the alkyl portion of choices (b) and (c) is optionally substituted with halogen or C1-4alkyl;
      • R6 is selected from the group consisting of:
        • (a) —C1-6alkylaryl,
        • (b) —C1-6alkylheteroaryl, and
        • (c) —C1-6alkyl(R7).
          wherein the alkyl portion of choices (a), (b), and (c) is optionally substituted with halogen or C1-4alkyl, and wherein the aryl portion of choice (a), and the heteroaryl portion of choice (b), are optionally mono- or di-substituted with substituents selected from halogen, nitro, CF3, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl. C3-6 cycloalkyl, C3-6cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen. —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC3-6cycloalkyl, and CN.
  • Within this sub-genus there is a class wherein:
      • R4 and R4′ are each independently selected from the group consisting of:
        • (a) —C(R7)(R8)OH,
        • (b) —N(R7)S(═O)2R8,
        • (c) —O—(R7),
        • (d) —C1-6alkyl-C(═O)OH,
        • (e) —C(═O)OH,
        • (f) —NHS(═O)2N(R7)(R8),
        • (g) C3-6cycloalkyl,
        • (h) CF3,
        • (i) heterocycle,
        • (j) —C1-6alkyl, and
        • (k) halogen,
          wherein the alkyl portion of choices (d) and (j), and the cycloalkyl portion of choice (g) are optionally mono- or di-substituted with halo, CN, aryl, C1-6alkyl, halo C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, or C3-6cycloalkoxy, and
          wherein the heterocycle of choice (i) is optionally mono- or di-substituted with substituents selected from halogen, hydroxyl, nitro, C1-6alkyl, C1-6alkoxy, halo C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkoxy, —NH(C1-6alkyl), —NH(C3-6cycloalkyl), —N(C1-6alkyl)2, —N(C3-6cycloalkyl)2, —S(═O)oC1-6alkyl, —S(═O)oC1-6cycloalkyl, and CN.
  • Within this class there is a sub-class wherein of Formula 1a
  • Figure US20240041837A1-20240208-C00005
  • or a pharmaceutically acceptable salt thereof.
  • Within this sub-class there is a sub-sub-class wherein of Formula 1b
  • Figure US20240041837A1-20240208-C00006
  • or a pharmaceutically acceptable salt thereof.
  • In some embodiments, R3 is not hydrogen. In some embodiments, R4 is not hydrogen. In some embodiments, R3 is not hydrogen; and R4 is not hydrogen.
  • In one aspect, described herein are the following compounds:
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-yl)acetic acid,
    • 3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-carboxylic acid,
    • 3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-carboxylic acid,
    • 1-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)cyclopropanecarboxylic acid,
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
    • 1-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)cyclopropanecarboxylic acid,
    • 1-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-yl)cyclopropanecarboxylic acid,
    • 3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methoxy-[1,1′-biphenyl]-3-carboxylic acid,
    • 3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-carboxylic acid,
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-propoxy-[1,1′-biphenyl]-3-yl)acetic acid,
    • N-(6-(3-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)phenyl)pyridin-3-yl)benzenesulfonamide,
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methoxy-[1,1-biphenyl]-3-yl)acetic acid,
    • 1-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methyl-[1,1′-biphenyl]-3-yl)cyclopropanecarboxylic acid,
    • 2-(4-(benzyloxy)-3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-(cyclopropylmethoxy)-[1,1′-biphenyl]-3-yl)acetic acid,
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-fluoro-[1,1′-biphenyl]-3-yl)acetic acid,
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-6-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
    • 3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-propoxy-[1,1′-biphenyl]-3-carboxylic acid,
    • N-((3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)methyl)benzenesulfonamide,
    • 3-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)4-methoxy-[1,1′-biphenyl]-3-yl)propanoic acid,
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1,1-difluoropropyl)-4-ethoxy-[1,1-biphenyl]-3-yl)acetic acid,
    • N-(6-(3-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1,1-difluoropropyl)phenyl)pyridin-3-yl)benzenesulfonamide,
    • 2-(5-(6-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-co-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyridin-2-yl)-2-methoxyphenyl)acetic acid,
    • 3-(3-(3′-(1H-tetrazol-5-yl)-[1,1′-biphenyl]-3-yl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one,
    • 2-(5-(4-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyrimidin-2-yl)-2-ethoxyphenyl)acetic acid,
    • 2-(5-(6-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyrimidin-4-yl)-2-ethoxyphenyl)acetic acid,
    • (3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-methoxy-[1,1′-biphenyl]-4-yl)acetic acid,
    • (3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-ethoxy-[1,1′-biphenyl]-4-yl)acetic acid,
    • (3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-propoxy-[1,1′-biphenyl]-4-yl)acetic acid,
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-hydroxy-[1,1′-biphenyl]-4-yl)acetic acid,
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-isopropoxy-[1,1′-biphenyl]-3-yl)acetic acid,
    • 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-(2-(dimethylamino)ethoxy)-[1,1′-biphenyl]-3-yl)acetic acid.
      or a pharmaceutically acceptable salt thereof.
  • In another aspect the invention is directed to a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • In another aspect the invention is directed to a method of treating a cancer which is negatively impacted by diminution in its metabolism of fatty acid, through the administration of a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
  • Within this aspect there is a genus wherein the cancer is selected from prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, and melanoma.
  • In another aspect the invention is directed to a method of treating cancer involving the administration of a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
  • In another aspect the invention is directed to a method of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers through the administration of a therapeutically effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
    • Definitions
  • The term “patient” includes mammals such as mice, rats, cows, sheep, pigs, rabbits, goats, horses, monkeys, dogs, cats, and humans.
  • The term “halo” or “halogen” refers to any radical of fluorine, chlorine, bromine or iodine.
  • The term “alkyl” refers to a saturated hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C1-6alkyl indicates that the group may have from 1 to 6 (inclusive) carbon atoms in it. Any atom can be optionally substituted, e.g., by one or more substitutents. Examples of alkyl groups include without limitation methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl and tert-butyl.
  • The term “haloalkyl” refers to an alkyl group, in which at least one hydrogen atom is replaced by halo. In some embodiments, more than one hydrogen atom (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) are replaced by halo. In these embodiments, the hydrogen atoms can each be replaced by the same halogen (e.g., fluoro) or the hydrogen atoms can be replaced by a combination of different halogens (e.g., fluoro and chloro). “Haloalkyl” also includes alkyl moieties in which all hydrogens have been replaced by halo (sometimes referred to herein as perhaloalkyl, e.g., perfluoroalkyl, such as trifluoromethyl). Any atom can be optionally substituted, e.g., by one or more substituents.
  • As referred to herein, the term “alkoxy” refers to a group of formula —O(alkyl). Alkoxy can be, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 2-pentoxy, 3-pentoxy, or hexyloxy. Likewise, the term “thioalkoxy” refers to a group of formula —S(alkyl). The terms “haloalkoxy” and “halothioalkoxy” refer to —O(haloalkyl) and —S(haloalkyl), respectively. The term “sulfhydryl” refers to —SH.
  • The term “aralkyl” refers to an alkyl moiety in which an alkyl hydrogen atom is replaced by an aryl group. One of the carbons of the alkyl moiety serves as the point of attachment of the aralkyl group to another moiety. Any ring or chain atom can be optionally substituted e.g., by one or more substituents. Non-limiting examples of“aralkyl” include benzyl, 2-phenylethyl, and 3-phenylpropyl groups.
  • The term “alkenyl” refers to a straight or branched hydrocarbon chain containing the indicated number of carbon atoms and having one or more carbon-carbon double bonds. Any atom can be optionally substituted, e.g., by one or more substituents. Alkenyl groups can include, e.g., vinyl, allyl, 1-butenyl, and 2-hexenyl.
  • The term “heterocycle” or “heterocyclic”, as used herein except where noted, represents a stable 4-, 5-, 6- or 7-membered monocyclic- or stable 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered fused bicyclic heterocyclic ring system which comprises at least one non-aromatic (i.e. saturated or partially unsaturated) ring which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and wherein the nitrogen heteroatom may optionally be quaternized. In the case of a “heterocycle” which is a bicyclic group, the second ring may also be a non-aromatic ring which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, as defined above, or the second ring may be a benzene ring, or a “cycloalkyl”, or a “cycloalkenyl”, as defined immediately below. Examples of such heterocyclic groups include, but are not limited to, azetidine, chroman, dihydrofuran, dihydropyran, dioxane, dioxolane, hexahydroazepine, imidazolidine, imidazoline, indoline, isochroman, isoindoline, isothiazoline, isothiazolidine, isoxazoline, isoxazolidine, morpholine, oxazoline, oxazolidine, oxetane, piperazine, piperidine, pyran, pyrazolidine, pyrazoline, pyrrolidine, pyrroline, tetrahydrofuran, tetrahydropyran, thiamorpholine, thiazoline, thiazolidine, thiomorpholine and N-oxides thereof.
  • The term “cycloalkyl” refers to a fully saturated monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon groups. Any atom can be optionally substituted, e.g., by one or more substituents. A ring carbon serves as the point of attachment of a cycloalkyl group to another moiety. Cycloalkyl moieties can include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, and norbornyl (bicycle[2.2.1]heptyl).
  • The term “cycloalkenyl” refers to partially unsaturated monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon groups. A ring carbon (e.g., saturated or unsaturated) is the point of attachment of the cycloalkenyl substituent. Any atom can be optionally substituted e.g., by one or more substituents. Cycloalkenyl moieties can include, e.g., cyclopentenyl, cyclohexenyl, cyclohexadienyl, or norbornenyl.
  • The term “cycloalkylene”, as used herein, refers to a divalent monocyclic cycloalkyl group having the indicated number of ring atoms.
  • The term “heterocycloalkylene”, as used herein, refers to a divalent monocyclic heterocyclyl group having the indicated number of ring atoms.
  • The term “aryl” as used herein, is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl, or biphenyl.
  • The term “heteroaryl”, as used herein except where noted, represents a stable 5, 6 or 7-membered monocyclic- or stable 9 or 10-membered fused bicyclic ring system which comprises at least one aromatic ring, —which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. In the case of a “heteroaryl” which is a bicyclic group, the second ring need not be aromatic and need not comprise a heteroatom. Accordingly, “heteroaryl” includes, for example, a stable 5, 6 or 7-membered monocyclic aromatic ring consisting of carbon atoms and from one to four heteroatoms, as defined immediately above, fused to a benzene ring, or fused to a “heterocycle”, “cycloalkyl”, or a “cycloalkenyl”, as defined above. Examples of such heteroaryl groups include, but are not limited to, benzimidazole, benzisothiazole, benzisoxazole, benzofuran, isobenzofuran, benzothiazole, benzothiophene, benzotriazole, benzoxazole, carboline, cinnoline, furan, furazan, imidazole, indazole, indole, indolizine, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, phthalazine, pteridine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and N-oxides thereof.
  • The term “acyl”, as used herein, refers to those groups derived from an organic acid by removal of the hydroxy portion of the acid. Accordingly, acyl is meant to include, for example, acetyl, propionyl, butyryl, decanoyl, pivaloyl, benzoyl and the like.
    • Compound Forms and Salts
  • The compounds of this invention may contain one or more stereocenters and thus occur as racemates and racemic mixtures, enantiomerically-enriched mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. The compounds of this invention may also be represented in multiple tautomeric forms, in such instances, the invention expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented. All such isomeric forms of such compounds are expressly included in the present invention.
  • The compounds of this invention include the compounds themselves, as well as their salts and their prodrugs, if applicable. A salt, for example, can be formed between an anion and a positively charged substituent (e.g., ammonium) on a compound described herein. Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate. Likewise, asalt can also be formed between a cation and a negatively charged substituent (e.g., carboxylate) on a compound described herein. Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion.
  • As used herein, “pharmaceutically acceptable salts” refer to derivatives wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, bu t are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. In one aspect of the invention the salts are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric, and tartaric acids.
  • When the compound of the present invention is acidic, salts may be prepared from pharmaceutically acceptable non-toxic bases, including inorganic and organic bases. Such salts that may be prepared include a lithium salt, sodium salt, potassium salt, magnesium salt, calcium salt, dicyclohexylamine salt, N-methyl-D-glucamine salt, tris(hydroxymethyl)methylamine salt, arginine salt, lysine salt, and the like.
  • Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418; Journal of Pharmaceutical Science, 66.2 (1977); and “Pharmaceutical Salts: Properties, Selection, and Use A Handbook; Wermuth, C. G, and Stahl, P. H. (eds.) Verlag Helvetica Chimica Acta, Zurich, 2002 [ISBN 3-906390-26-8] each of which is incorporated herein by reference in their entireties.
  • The compounds may be radiolabeled with radioactive isotopes, such as for example tritium, iodine-125 or carbon-14. All isotopic variations of the compounds of the invention, whether radioactive or not, are intended to be encompassed within the scope of the invention.
  • In some embodiments, hydrogen atoms of the compounds described herein may be replaced with deuterium atoms.
  • In some embodiments, compounds of Formula I are prepared as prodrugs. Prodrugs are generally dng precursors that, following administration to a subject and subsequent absorption, are converted to an active, or a more active species via some process, such as conversion by a metabolic pathway. Examples of prodrugs include C1-6 alkyl esters of carboxylic acid groups, which, upon administration to a subject, are capable of providing active compounds.
    • Pharmaceutical Compositions
  • The term “pharmaceutically acceptable carrier” refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, or a pharmaceutically acceptable salt thereof, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
  • The term “composition” as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. Such term in relation to pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the terms “administration of” or “administering a” compound shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs,” ed. H. Bundgaard, Elsevier, 1985. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.
  • The amount administered depends on the compound formulation, rote of administration, etc, and is generally empirically determined in routine trials, and variations will necessarily occur depending on the target, the host, and the route of administration, etc. Generally, the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1, 3, 10 or 30 to about 30, 100, 300 or 1000 mg, according to the particular application. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
    • Uses
  • In one aspect the invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. In another aspect the invention is directed to a method of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα, antagonist. The methods include administering to the subject an effective amount of a compound of Formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein. In another aspect, the use of a compound of Formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein in the preparation of, or for use as, a medicament for the treatment (e.g., controlling, alleviating, or slowing the progression of) or prevention (e.g., delaying the onset of or reducing the risk of developing) of one or more diseases, disorders, or conditions caused by, or associated with, prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers.
  • In one aspect the invention is directed a method of treating a cancer which is negatively impacted by diminution in its metabolism via fatty acid oxidation, comprising administration of a therapeutically effective amount of a compound of Formula I (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt). In another aspect, the invention is directed to a method of treating a cancer having a metabolism that is reliant on fatty acid oxidation, comprising administration of a therapeutically effective amount of a compound of Formula I (and/or a compound of any of the other formulae described herein), or a pharmaceutically acceptable salt thereof.
    • Administration
  • The compounds and compositions described herein can, for example, be administered orally, parenterally (e.g., subcutaneously, intracutaneously, intravenously, intramuscularly, intraarticularly, intraarterially, intrasynovially, intrasternally, intrathecally, intralesionally and by intracranial injection or infusion techniques), by inhalation spray, topically, rectally, nasally, buccally, vaginally, via an implanted reservoir, by injection, subdermally, intraperitoneally, transmucosally, or in an ophthalmic preparation, with a dosage ranging from about 0.01 mg/kg to about 1000 mg/kg, (e.g., from about 0.01 to about 100 mg/kg, from about 0.1 to about 100 mg/kg, from about 1 to about 100 mg/kg, from about 1 to about 10 mg/kg) every 4 to 120 hours, or according to the requirements of the particular drug. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep. 50, 219 (1966). Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, N.Y., 537 (1970). In certain embodiments, the compositions are administered by oral administration or by injection. The methods herein include the administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.
  • Dosage forms include from about 0.05 milligrams to about 2,000 milligrams (e.g., from about 0.1 milligrams to about 1,000 milligrams, from about 0.1 milligrams to about 500 milligrams, from about 0.1 milligrams to about 250 milligrams, from about 0.1 milligrams to about 100 milligrams, from about 0.1 milligrams to about 50 milligrams, or from about 0.1 milligrams to about 25 milligrams) of a compound of Formula I (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein. The dosage forms can further include a pharmaceutically acceptable carrier and/or an additional therapeutic agent.
  • In one aspect the compounds of the invention may be co-administered with one or more additional anti-cancer agents. The additional anti-cancer agents include, but are not limited to alkylating agents such as cyclophosphamide, chlorambucil, mecloreethamine, ifosfamide, or melphalan; antimetabolites such as methotrexate, cytarabine, fludarabine, 6-mercaptopurine, azathioprene, pyrimidines, or 5-fluorouracil; antimitotic agents such as vincristine, paclitaxel, vinorelbine or docetaxaxel; a topoisomerase inhibitors such as doxorubicin or irinotecan; platinum derivatives such as cisplatin, carboplatin or oxaliplatin; hormone therapeutics such as tamoxifen; aromatase inhibitors such as bicalutamide, anastrozole, exemestane or letrozole; signaling inhibitors such as imatinib, gefitinib or erlotinib; monoclonal antibodies such as rituximab, trastuzumab, gemtuzumab or ozogamicin; differentiating agents such as tretinoin or arsenic trioxide; antiangiogenic agents such as bevacizumab, sorafinib or sunitinib; biologic response modifiers such as interferon-alpha; topoisomerase inhibitors such as camptothecins (including irinotecan and topotecan), amsacrine, etoposide, etoposide phosphate, or teniposide; cytotoxic antibiotics such as actinomycin, anthracyclines including doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin or mitomycin; vinca alkaloids such as vincristine, vinblastine, viorelbine or vindesine; or podophyllotoxins such as etoposide and teniposide; or mTOR inhibitors such as rapamycin, temsirolimus and everolimus.
  • Other anti-cancer agents for use in combination with the compounds include one or more of the following: abiraterone, adriamycin, dactinomycin, bleomycin, vinblastine, cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa, bicalutamide; bisantrenehydrochloride; bisnafidedimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine, everolimus; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin II (including recombinant interleukin II, or rlL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-1 a; interferon gamma-1 b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; metformin, methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantronehydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; rapamycin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; temsirolimus; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate, triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride.
  • In certain embodiments, the additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention (e.g., sequentially, or on different overlapping schedules with the administration of one or more compounds of Formula (I) (and/or a compound of any of the other formulae including any subgenera or specific compounds thereof)). In other embodiments, these agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition. In still another embodiment, these agents can be given as a separate dose that is administered at about the same time as one or more compounds of Formula (I) (and/or a compound of any of the other formulae including any subgenera or specific compounds thereof) are administered (e.g., simultaneously with the administration of one or more compounds of Formula (I) (and/or a compound of any of the other formulae including any subgenera or specific compounds thereof)). When the compositions of this invention include a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent can be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
  • The compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
  • The compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase that is then combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
    • Biological Function
  • The utility of the invention can be demonstrated by one or more of the following methods or other methods known in the art:
  • Human PPARα Reporter Assay
  • The screening of test compounds for agonist or antagonist activities against human PPARα receptors was performed using a commercial kit, Human PPARα Reporter Assay System (Indigo Biosciences, Cat. #1B00111).
  • This nuclear receptor assay system utilizes proprietary non-human mammalian cells engineered to provide constitutive, high-level expression of Human PPARα. Because these cells incorporate a PPARα-responsive luciferase reporter gene, quantifying expressed luciferase activity provides a sensitive surrogate measure of PPARα activity in the treated cells. The primary application of this reporter assay system is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against human PPARα. While this assay may be used to measure agonism, each of the Examples, infra, exhibits antagonism rather than agonism. Briefly, the reporter cells are dispensed into wells of the assay plate and then immediately dosed with test compounds. Following an overnight incubation, the treatment media are discarded and Luciferase Detection Reagent (LDR) is added. The intensity of light emission from the ensuing luciferase reaction provides a sensitive measure that is directly proportional to the relative level of PPARα activation in the reporter cells.
  • Target Selectivity Assays
  • To determine species selectivity, a Mouse PPARα Reporter Assay System was used (Indigo Biosciences, Cat. #M00111). Activity of test compounds to antagonize or agonize other isoforms of human PPAR, for example β/δ and γ, were assessed using the corresponding kits from Indigo Biosciences (Cat. #IB00121 and #IB00101, respectively). In addition to PPAR activity, compounds were also screened for activity against other nuclear hormone receptors including Estrogen Receptor β, Glucocorticoid Receptor and Thyroid Receptor β using commercially available kits (Indigo Biosciences, Cat. #IB00411, IB00201 and IB01101, respectively). Each assay system from Indigo Biosciences uses technology analogous to the human PPARα kit, with the variance being that the cells used for each assay were engineered to over-express the receptor of interest. In addition, the appropriate receptor agonist (included with each kit) was used at ˜EC80 for assays in which antagonist potency was being assessed.
  • Target Selectivity—Counterscreen Assay Results
  • PPAR PPAR PPAR Thyroid Gluco- Estrogen
    alpha beta/delta gamma Receptor corticoid Receptor
    IC50 IC50 IC50 β Receptor β
    Example (nM) (nM) (nM) IC50 (nM) IC50 (nM) IC50 (nM)
    6 58 13265 39845 30849 18191 19444
  • Measuring Fatty Acid Oxidation Using 3H Palmitate
  • Fatty acid oxidation is measured using 3H palmitate metabolism into 3H2O as described previously (Nieman et al., 2011). Briefly, cells (e g. HepG2, PC3 and CLL) are plated in growth media and allowed to adhere overnight. Cells are then treated with compound or 40 μM etomoxir (an inhibitor of fatty acid oxidation) as control. After treatment, cells are washed with DPBS followed by incubation in assay buffer (growth media, 3H palmitate and compound). After incubation, media is collected and proteins precipitated with 5% tricholoroacetic acid. The precipitate is pelleted by centrifugation and the supernatant collected. Any remaining 3H palmitate in the supernatant is then removed by purification over a Dowex anion exchange column. 3H2O is then measured by scintillation counting.
  • Measurement of Cell Viability
  • Purified CLL cells were cultured at 2×105 cells/200 μL of RPMI1640 supplemented with 10% FCS in 96-well plates under various treatment conditions. Determination of CLL cell viability was based on the analysis of mitochondrial transmembrane potential (ΔΨm) using 3,3′-dihexylaxacarbocyanine iodide (DiOC6) (Invitrogen) and cell membrane permeability to propidium iodide (PI) (Sigma). For viability assays, 100 μL of the cell culture was collected at the indicated time points and transferred to polypropylene tubes containing 100 μL of 40 μM DiOC6 and 10 μg/mL PI in culture media. The cells were then incubated at 37° C. for 15 min and analyzed within 30 min by flow cytometry using an Accuri C6 flow cytometer. The percentage of viable cells was determined by gating on PI negative and DiOC6 bright cells.
  • In vivo PD model; PPAR alpha agonist-induced changes in liver gene expression
  • CD-1 mice were treated with test compound 1-2 hours prior to oral gavage with the PPAR alpha agonist WY14,643 (3 mg/kg). For the 1 day pharmacodynamic model, animals were euthanized 6 hours after agonist treatment. For the 3 day pharmacodynamic model, mice were dosed again with antagonist and WY14,643 on day 2 and day 3. In this case, mice were euthanized 6 hours following WY14,643 on day 3. Upon termination, blood was collected for DMPK analysis. Liver was collected, placed into Trizol and stored at −80° C. until processing. RNA was extracted from thawed and homogenized tissue using standard Trizol RNA isolation methods. RT-PCR was performed on the extracted RNA using primers specific for PPAR alpha regulated genes. Quantitative PCR was performed on the resulting cDNA and expression was normalized to β-actin.
  • In Vivo Cancer Model; B16F10 Model of Pulmonary Metastasis
  • B16F10 cells were cultured in standard growth media, harvested when approximately 50% confluent and injected into C57BL/6 mice via the tail vein (50,000 cells per mouse in 200 μL). Mice were treated daily with test compound. On day 21, mice were euthanized. Lungs were harvested and placed into Fekete's solution overnight to facilitate visualization of the tumors. Black nodules were enumerated.
  • FIG. 1 shows inhibition of metastasis of B16F10 melanoma cells to the lung following oral doses of Example 6 at 0.3, 3 and 30 mg/kg. Statistics were performed by ANOVA with Dunnett's Multiple Comparison Test post-hoc to determine statistical differences from vehicle treatment group. * denotes P<0.05, while *** denotes P<0.001.
    • Synthesis
  • The starting materials used for the synthesis are either synthesized or obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Fluka. Acros Organics, Alfa Aesar, VWR Scientific, and the like. General methods for the preparation of compounds can be modified by the use of appropriate reagents and conditions for the introduction of the various moieties found in the structures are provided herein.
  • In some embodiments, compounds described herein are prepared as outlined in the following general synthetic scheme.
    • General Synthetic Scheme for Exemplary Compounds
  • Figure US20240041837A1-20240208-C00007
  • For Heterocycle Containing Central Rings:
  • Figure US20240041837A1-20240208-C00008
    • Preparation of Intermediates 4-(3-Bromophenyl)butanoic acid
  • Figure US20240041837A1-20240208-C00009
  • Step 1: To a solution of 3-bromobenzaldehyde (5.00 g, 27.0 mmol) in DMF (18 mL) was added sodium cyanide (331 mg, 6.8 mmol) and the resulting solution was heated at 45° C. for 30 min. A solution of acrylonitrile (1.55 mL, 23.7 mmol) in DMF (2 mL) was added dropwise over a period of 20 minutes and the heating continued for 3 hrs. The solution was allowed to cool after which AcOH (1 mL) was added, the reaction mixture partitioned between EtOAc and water, the organic phase extracted, dried (MgSO4), filtered and evaporated in vacuo. The residue was purified using silica gel chromatography (0 to 30% EtOAc in hexanes) to afford 3.1 g of 4-(3-bromophenyl)-4-oxobutanenitile as a yellow oil.
  • Step 2: To a solution of the isolated nitrile (3.1 g, 13.0 mmol) in ethylene glycol (22 mL) was added water (0.5 mL), hydrazine monohydrate (1.5 mL) and potassium hydroxide (3.34 g). The reaction mixture was heated to 195° C. until analysis by LCMS indicated complete reaction, after which it was allowed to cool to room temperature, diluted with water and acidifed to pH ˜2 with 2N HCl. The resulting solution was extracted with EtOAc, dried (MgSO4), filtered and evaporated in vacuo. Purification of the residue on silica gel (0 to 30% acetone in hexanes) afforded 2.9 g of the title acid.
    • 4-(3-Bromophenyl)butanehydrazide
  • Figure US20240041837A1-20240208-C00010
  • To a solution of 4-(3-bromophenyl)butanoic acid (2.9 g, 11.9 mmol) in THF (50 mL) was added carbonyldiimidazole (2.32 g, 14.3 mmol) and stirred for 1.5 hrs. Hydrazine monohydrate (2.4 mL, ˜4 eq.) was added and the reaction was complete after 30 minutes as judged by LCMS analysis. The solution was partitioned between EtOAc and water, the organic phase extracted, dried (MgSO4), filtered and evaporated to afford the title compound which was then used without further purification.
    • 3-(3-(3-Bromophenyl)propyl)-4-ethyl-H-1,2,4-triazol-5(4H)-one
  • Figure US20240041837A1-20240208-C00011
  • Step 1: The previously isolated 4-(3-bromophenyl)butanehydrazide (11.9 mmol) was dissolved in THF (50 mL) to which was added ethyl isocyanate (1.13 mL, 14.3 mmol). After stirring at room temperature for 12 hrs. the solution was evaporated to dryness to afford 2-(4-(3-bromophenyl)butanoyl)-N-ethylhydrazinecarboxamide which was then used without further purification.
  • Step 2: To a solution of the isolated carboxamide in MeOH (50 mL) was added KOH (6 g) and the reaction mixture was heated to reflux for 16 hrs. After complete reaction as judged by LCMS analysis, the solvent was removed and the residue diluted in DCM and acidified with 1N HCl with cooling. Extraction of the resulting mixture with DCM, drying of the organic phase (MgSO4), filtration and evaporation of the filtrate in vacuo afforded crude 3-(3-(3-bromophenyl)propyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one which could be purified on silica gel (0 to 100% EtOAc in hexanes).
    • 3-(3-(3-Bromophenyl)propyl)-1-(4-(eft-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one
  • Figure US20240041837A1-20240208-C00012
  • To a solution of 3-(3-(3-bromophenyl)propyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (27.7 g, 89.3 mmol) in DMF (200 mL) was added potassium carbonate (40.0 g, 288.7 mmol) followed by 4-tert-butylbenzylbromide (17.2 mL, 93.8 mmol) and the resulting suspension was stirred vigorously for 48 hrs at room temperature. The reaction mixture was diluted with EtOAc, washed with water (×2), dried (MgSO4), filtered and evaporated in vacuo. Purification of the residue on silica gel (0 to 50% EtOAc in hexanes) afforded the title compound as a colorless oil.
    • 1-(4-(tert-Butyl)benzyl)-4-ethyl-3-(3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1H-1,2,4-triazol-5(4H)-one
  • Figure US20240041837A1-20240208-C00013
  • To a solution of 3-(3-(3-bromophenyl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (11.7 g, 25.5 mmol) in dioxane (150 mL) was added potassium acetate (7.5 g, 76.5 mmol), bis(pinacolato)diboron (7.8 g, 30.7 mmol) and Pd(dppf)Cl2 (750 mg). The resulting solution was sparged with dry nitrogen for 15 minutes and then heated to 85° C. for a period of 3 hrs. The solvent was removed in vacuo and the residue partitioned between EtOAc and water. The organic phase was separated, dried (MgSO4), filtered and evaporated to give the crude boronate. This was further purified on silica gel, eluting with 0 to 50% EtOAc in hexanes, to afford the title boronate as a colorless oil.
    • Methyl 2-(5-bromo-2-hydroxyphenyl)acetate
  • Figure US20240041837A1-20240208-C00014
  • To a solution of 2-(2-hydroxyphenyl)acetic acid (15.6 g, 103 mmol) in MeOH (350 mL) was added tetrabutylammonium tribromide (50 g, 103 mmol) in small portions over a 10 minute period. After stirring at ambient temperature for 24 hrs, the solvent was evaporated and the residue taken up in EtOAc, washed with 1N HCl, extracted with EtOAc, the organic phases dried (MgSO4), filtered and evaporated. The residue was purified on silica gel eluting with a gradient of 30% EtOAc in hexanes to afford the title compound as a colorless solid.
    • Methyl 2-(5-bromo-2-ethoxyphenyl)acetate
  • Figure US20240041837A1-20240208-C00015
  • To a solution of methyl 2-(5-bromo-2-hydroxyphenyl)acetate (1.0 g, 4.1 mmol) in DMF (8 mL) was added cesium carbonate (2.66 g, 8.2 mmol) and iodoethane (392 μL, 4.9 mmol) and stirred at rt for 2 hrs. After completion, the reaction mixture was partitioned between EtOAc and water, the organic phase separated, washed with water, dried (MgSO4), filtered and evaporated in vacuo. The residue was purified on silica gel eluting with a gradient of 0 to 10% EtOAc in hexanes to afford the title compound as a colorless oil.
    • Methyl 2-(5-bromo-2-methoxyphenyl)acetate
  • Figure US20240041837A1-20240208-C00016
  • Prepared in an analogous fashion to the aforementioned ethyl derivative using methyl iodide as electrophile.
    • Methyl 2-(5-bromo-2-propoxyphenyl)acetate
  • Figure US20240041837A1-20240208-C00017
  • Prepared in an analogous fashion to the aforementioned ethyl derivative using 1-bromopropane as electrophile.
    • Methyl 2-(2-(benzyloxy)-5-bromophenyl)acetate
  • Figure US20240041837A1-20240208-C00018
  • Prepared in an analogous fashion to the aforementioned ethyl derivative using benzylbromide as electrophile.
    • Methyl 2-(5-bromo-2-(cyclopropylmethoxy)phenyl)acetate
  • Figure US20240041837A1-20240208-C00019
  • Prepared in an analogous fashion to the aforementioned ethyl derivative using (bromomethyl)cyclopropane as electrophile.
    • Methyl 2-(5-bromo-2-(2-(dimethylamino)ethoxy)phenyl)acetate
  • Figure US20240041837A1-20240208-C00020
  • Prepared in an analogous fashion to the aforementioned ethyl derivative using 2-chloro-N,N-dimethylamine hydrochloride as electrophile in the presence of catalytic amount of tetrabutylammonium iodide. Purified on silica using a 0 to 60% gradient of acetone in hexanes.
    • Methyl 5-bromo-2-propoxybenzoate
  • Figure US20240041837A1-20240208-C00021
  • Prepared in an analogous fashion to methyl 2-(5-bromo-2-ethoxyphenyl)acetate but star ting with 5-bromo-methylsalicylate as starting material.
    • 2-(4-Bromo-2-methoxyphenyl)acetonitrile
  • Figure US20240041837A1-20240208-C00022
  • Step 1: To a solution of 5-bromo-2-methylphenol (1.5 g, 8.0 mmol) in DMF (10 mL) was added Cs2CO3 (3.9 g, 12.0 mmol) followed by iodomethane (0.55 mL, 8.8 mmol). The resulting suspension was stirred vigorously for 24 hrs after which it was diluted with EtOAc and washed with water. The organic phase was dried (MgSO4), filtered, evaporated in vacuo and the residue purified on silica gel (0 to 5% EtOAc gradient in hexanes) to afford 4-bromo-2-methoxy-1-methylbenzene as a colorless oil.
  • Step 2: To a solution of 4-bromo-2-methoxy-1-methylbenzene (1.2 g, 6.0 mmol) in CCl4 (15 mL) was added N-bromosuccinimide (1.17 g, 6.5 mmol) and benzoyl peroxide (50 mg). The resulting mixture was heated under reflux for 6 hrs, allowed to cool, evaporated and the residue purified on silica gel eluting with a gradient of 0 to 10% EtOAc in hexanes. The isolated bromide (440 mg, 1.6 mmol) was then dissolved in DMF (2 mL) and potassium cyanide (204 mg, 3.1 mmol) added. After stirring for 48 hrs at room temperature, the solution was diluted with EtOAc, washed with water, the organic phase separated, dried (MgSO4), filtered and evaporated in vacuo. Purification of the residue on silica gel (0 to 10% EtOAc in hexanes) afforded the title compound.
    • 2-(4-Bromo-2-ethoxyphenyl)acetonitrile
  • Figure US20240041837A1-20240208-C00023
  • Prepared in an analogous fashion to the methoxy derivative using iodoethane in Step 1.
    • 2-(4-Bromo-2-propoxyphenyl)acetonitrile
  • Figure US20240041837A1-20240208-C00024
  • Prepared in an analogous fashion to the methoxy derivative using 1-bromopropane in Step 1.
    • 2-(5-Bromo-2-isopropoxyphenyl)acetonitrile
  • Figure US20240041837A1-20240208-C00025
  • Prepared in an analogous fashion to 2-(4-bromo-2-ethoxyphenyl)acetonitrile utilizing 4-bromo-2-methylphenol as starting material and alkylating the phenol under the following conditions: To a solution of 4-bromo-2-methylphenol (3.5 g, 18.7 mmol) in DMSO (10 mL) was added K2CO3 (5.2 g, 37.5 mmol) and 2-iodopropane (2.25 mL, 22.5 mmol) and the resulting suspension was heated to 60° C. in a sealed vial for 16 hrs. After complete reaction the solution was diluted in EtOAc, washed with water, the organic phase separated, dried (MgSO4), filtered and evaporated in vacuo. The isolated residue was purified on silica gel (0 to 5% EtOAc in hexanes) to afford 4-bromo-1-isopropoxy-2-methylbenzene as a colorless oil.
    • 1-(4-(ter-Butyl)benzyl)-N-ethylhydrazinecarboxamide, monomethanesulfonate (Intermediate M)
  • Figure US20240041837A1-20240208-C00026
  • Step 1: In a 500 mL Parr shaker flask was dissolved (E)-tert-butyl 2-(4-(tert-butyl)benzylidene)hydrazine-carboxylate (15.0 g, 54.0 mmol, prepared according to the procedure described in Braden, T. M. et al., Org. Process Res. Dev. 2007, 11, 431-440) in iPrOH (75 mL) and EtOAc (25 mL). To this was then added Adam's catalyst (0.7 g, 0.3 mmol) and the resulting suspension was thoroughly deoxygenated via subsurface purging with nitrogen. The reaction vessel was then connected to a Parr shaker and the reaction suspension was shaken under 50 psi of H2 for 3 days (or until no further consumption of hydrogen gas could be discerned). At this point, the excess H2 was discharged from the vessel and the reaction was immediately quenched with DCM. The deactivated catalyst was then removed via filtration through a pad of DCM-wetted celite and the insolubles were washed thoroughly with DCM. The filtrate thus obtained was concentrated in vacuo to furnish a colorless oil. This residue was then transferred as an iPrOH (100 mL) solution to a 500 mL Parr shaker flask and added another batch of Adam's catalyst (0.7 g, 0.3 mmol). After de-oxygenation via subsurface purging with nitrogen, the resulting suspension was shaken under 50 psi of H2 for 2 more days. Finally, excess H2 was discharged from the vessel and the reaction was quenched with DCM. The insolubles were then removed via filtration through a pad of DCM-wetted celite and the celite bed was washed thoroughly with DCM. Concentration of the filtrate thus obtained in vacuo furnished 15.1 g of tert-butyl 2-(4-(tert-butyl)benzyl)hydrazinecarboxylate (quantitative yield).
  • Step 2: In an oven-dried 1 L RBF equipped with a magnetic stirrer was dissolved tert-butyl 2-(4-(tert-butyl)benzyl)hydrazinecarboxylate (15.1 g, 54.0 mmdl) in anhydrous DCM (500 mL). To this was then added neat ethyl isocyanate (6.7 mL, 86 mmol) drop-wise over a period of 15 min and the resulting solution was allowed to stir under nitrogen at RT over 48 h. The volatiles were then removed in vacuo and the resulting residue was co-evaporated with heptanes (3×500 mL) to furnish 19.5 g of tert-butyl 2-(4-(tert-butyl)benzyl)-2-(ethylcarbamoyl)hydrazinecarboxylate (quantitative yield).
  • Step 3: In an oven-dried 1 L RBF equipped with a magnetic stirrer was dissolved tert-butyl 2-(4-(tert-butyl)benzyl)-2-(ethylcarbamoyl)hydrazinecarboxylate (19.5 g, 54.0 mmol) in anhydrous DCM (500 mL). To this was then added neat MsOH (4.7 mL, 73 mmol) drop-wise over a period of 15 min and the resulting solution was allowed to stir under nitrogen at RT over 16 h. The volatiles were then in vacuo and the resulting residue was co-evaporated with DCM (3×500 mL) and MeOH (3×500 mL) to furnish 19.1 g (99% yield) of intermediate (M) as a pale yellow foam.
    • Example 1: 2-(3′-(3-(1-(4-(tert-Butyl)benzyl)4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid
  • Figure US20240041837A1-20240208-C00027
  • Step 1: To a solution of 3-(3-(3-bromophenyl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (250 mg, 0.55 mmol) in a mixture of DME (5 mL) and water (2 mL) was added potassium carbonate (191 mg, 1.38 mmol) and 3-ethoxycarbonylmethylphenylboronic acid (191 mg, 0.66 mmol). After sparging the mixture with nitrogen, Pd(PPh3)4 (30 mg, cat.) was added and the reaction heated at 85° C. for 3 hrs. The reaction as allowed to cool, partitioned between EtOAc and water, the organic phase extracted, dried (MgSO4), filtered and evaporated in vacuo. The residue was purified on silica gel eluting with a gradient of 0 to 60% EtOAc in hexanes to afford the ester of the title compound.
  • Step 2: To a solution of the aforementioned ester (200 mg, 0.37 mmol) in a mixture of THF (4 mL), MeOH (2 mL) and water (2 mL) was added lithium hydroxide monohydrate (100 mg, 2.4 mmol) and the reaction stirred at room temperature until complete ester hydrolysis was evident as determined by LCMS analysis. Solid citric acid was added to adjust pH to ˜4 and the solution partitioned between EtOAc and water. The organic phase was extracted, dried (MgSO4), filtered and evaporated to afford the title acid as a colorless solid.
  • The following examples (2-4.6-11, 13, 15-19, 28-30, 32 and 33) were prepared in an analogous fashion to Example 1 using the requisite commercially available boronic acid (or pinacol ester) coupling partner and subsequent hydrolysis.
    • Example 2: 2-(3′-(3-(1-(4-(tert-Butyl)benzyl)ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-yl)acetic acid
  • Figure US20240041837A1-20240208-C00028
    • Example 3: 3′-(3-(1-(4-(tert-Butyl)benzyl)-4ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-carboxylic acid
  • Figure US20240041837A1-20240208-C00029
    • Example 4: 3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-carboxylic acid
  • Figure US20240041837A1-20240208-C00030
    • Example 5: 1-(3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)cyclopropanecarboxylic acid
  • Figure US20240041837A1-20240208-C00031
    • Preparation of 1-(5-bromo-2-ethoxyphenyl)cyclopropanecarbonitrile
  • Figure US20240041837A1-20240208-C00032
  • Step 1: To a solution of 4-bromo-2-methylphenol (5.0 g, 26.7 mmol) in DMF (20 mL) was added Cs2CO3 (13.0 g, 39.9 mmol) and iodoethane (2.6 mL, 32.5 mmol). The reaction was stirred vigorously for 24 hrs after which the suspension was partitioned between EtOAc and water, the organic phase extracted, wash with water, dried (MgSO4), filtered and evaporated to afford 4-bromo-1-ethoxy-2-methylbenzene used without further purification.
  • Step 2: To a solution of 4-bromo-1-ethoxy-2-methylbenzene (5.0 g, 23.1 mmol) in CCl4 (80 mL) was added N-bromosuccinimide (4.93 g, 27.6 mmol) and benzoyl peroxide (100 mg, cat.). The reaction mixture was then heated to reflux for a period of 3 hrs after which it was allowed to cool, partially evaporated then filtered to remove the succinimide. The filtrate was then evaporated to dryness to afford the benzylbromide which was used without further purification.
  • Step 3: To the crude 4-bromo-2-(bromomethyl)-1-ethoxybenzene (23.1 mmol) isolated previously was added DMF (20 mL) and potassium cyanide (2.26 g, 34.7 mmol) and the slurry stirred at room temperature for 48 hrs. The reaction mixture was partitioned between EtOAc and water, the organic phase separated, dried (MgSO4), filtered and evaporated to afford a mixture of the mono and bis cyanomethyl derivatives. Purification of the mixture using silica gel chromatography (0 to 10% EtOAc in hexanes) afforded 2.5 g of 2-(5-bromo-2-ethoxyphenyl)acetonitrile.
  • Step 4: To 2-(5-bromo-2-ethoxyphenyl)acetonitrile (1.0 g, 4.16 mmol) in 2 mL of aqueous KOH (50%) was added tetrabutylammonium bromide (200 mg) and 1,2-dibromoethane (541 μL, 6.2 mmol) and heated in a sealed vial at 50° C. with vigorous stirring for 4 hrs. The mixture was partitioned between EtOAc and 1N HCl, the organic phase separated, dried (MgSO4), filtered and evaporated in vacuo. The afforded 1-(5-bromo-2-ethoxyphenyl)cyclopropanecarbonitrile was used without further purification.
  • Example 5 was prepared analogously to example 1 using 1-(5-bromo-2-ethoxyphenyl)cyclopropanecarbonitrile as the coupling partner. Furthermore, hydrolysis of the resulting nitrile after cross-coupling was performed using KOH in ethylene glycol and water at 150° C.
    • Example 6: 2-(3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid
  • Figure US20240041837A1-20240208-C00033
    • Example 7: 1-(3′-(3-(1-(4-(tert-Butyl)benzyl)-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)cyclopropanecarboxylic acid
  • Figure US20240041837A1-20240208-C00034
    • Example 8: 1-(3′-(3-(1-(4-(tert-Butyl)benzyl)4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-yl)cyclopropanecarboxylic acid
  • Figure US20240041837A1-20240208-C00035
    • Example 9: 3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methoxy-[1,1′-biphenyl]-3-carboxylic acid
  • Figure US20240041837A1-20240208-C00036
    • Example 10: 3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-VI)propyl)-4-ethoxy-[1,1′-biphenyl]-3-caboxylic acid
  • Figure US20240041837A1-20240208-C00037
    • Example 11: 2-(3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-propoxy-[1,1′-biphenyl]-3-yl)acetic acid
  • Figure US20240041837A1-20240208-C00038
    • Example 12: N-(6-(3-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)phenyl)pyridin-3-VI)benzenesulfonamide
  • Figure US20240041837A1-20240208-C00039
  • Step 1: To a solution of 3-(3-(3-bromophenyl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (300 mg, 0.6 mmol) in a mixture of DME (5.5 mL) and water (2.5 mL) was added potassium carbonate (250 mg, 1.80 mmol) and 3-amino-6-bromopyridine (135 mg, 0.78 mmol). After sparging the mixture with nitrogen, Pd(PPh3)4 (30 mg, cat.) was added and the reaction heated at 85° C. for 6 hrs. The reaction was allowed to cool, partitioned between EtOAc and water, the organic phase extracted, dried (MgSO4), filtered and evaporated in vacuo. The residue was purified on silica gel eluting with a gradient of 0 to 60% EtOAc in hexanes to afford 3-(3-(3-(5-aminopyridin-2-yl)phenyl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one.
  • Step 2: To a solution of the isolated 3-(3-(3-(5-aminopyridin-2-yl)phenyl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (50 mg, 0.106 mmol) in pyridine (0.8 mL) was added benzenesulfonyl chloride (14 μL, 0.106 mmol). After stirring for 48 hrs, the reaction mixture was diluted with EtOAc, washed with water, dried (MgSO4), filtered and evaporated in vacuo. The isolated residue was purified on silica gel eluting with a gradient of 0 to 5% MeOH in CHCl3 to afford the title compound.
    • Example 13: 2-(3′-(3-(1-(4-(tert-Butyl)benzyl)-4-th-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methoxy-[1,1′-biphenyl]-3-yl)acetic acid
  • Figure US20240041837A1-20240208-C00040
    • Example 14: 1-(3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methyl-[1,1′-biphenyl]-3-yl)cyclopropanecarboxylic add
  • Figure US20240041837A1-20240208-C00041
    • Preparation of 1-(5-bromo-2-methylphenyl)cyclopropanecarbonitrile
  • Figure US20240041837A1-20240208-C00042
  • Step 1: To a suspension of LiAlH4 (0.75 g, 3.11 mmol) in diethyl ether (8 mL) at 0° C. was added a solution of methyl 5-bromo-2-methylbenzoate (949 mg, 4.14 mmol) in diethyl ether (2 mL) dropwise. The reaction mixture was allowed to slowly warm tort, then quenched with EtOAc, partitioned between EtOAc and 2N HCl and extracted (EtOAc). The organic phase was washed with water, dried (MgSO4), filtered and evaporated in vacuo to afford the crude alcohol which can be used without further purification
  • Step 2: To the aforementioned alcohol (818 mg, 4.1 mmol) in diethyl ether (10 mL) cooled to 0° C. was added PBr3 (0.2 ml, 2.07 mmol) and stirred at 0° C. for 1 hr. The reaction was then quenched with water, diluted with ether, washed with sodium bicarbonate solution, the organic phase separated and dried (MgSO4), filtered and evaporated yielding 726 mg of the benzyl bromide.
  • Step 3: To 4-bromo-2-(bromomethyl)-1-methylbenzene (726 mg, 2.75 mmol) in DMF (8 mL) was added sodium cyanide (142 mg, 2.89 mmol) and the resulting suspension heated to 50° C. for 4 hrs. The reaction mixture was diluted with EtOAc, washed with water then brine, dried (MgSO4), filtered and evaporated in vacuo. The isolated residue was purified on silica gel eluting with a gradient of 0 to 50% EtOAc in hexanes to afford 2-(5-bromo-2-methylphenyl)acetonitrile.
  • Step 4: 1-(5-bromo-2-methylphenyl)cyclopropanecarbonitrile was then prepared analogously to the method described in Example 5, Step 4.
  • Example 14 was completed under the same conditions as described for Example 5.
    • Example 15: 2-(4-(Benzyloxy)-3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid
  • Figure US20240041837A1-20240208-C00043
    • Example 16: 2-(3′-(3-(1-(4-(If-Butyl)benzyl)-ethyl-5-oxo-4,5-dihydro-H-1,2,4-triazol-3-yl)propyl)-4-(cyclopropylmethoxy)-[1,1′-biphenyl]-3-yl)acetic acid
  • Figure US20240041837A1-20240208-C00044
    • Example 17: 2-(3′-(3-(1-(4-(tert-Butyl)benzyl)-4ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)4-fluoro-[1,1′-biphenyl]-3-yl)acetic acid
  • Figure US20240041837A1-20240208-C00045
    • Example 18: 2-(3′-(3-(1-(4-(tert-Butyl)benzyl)4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-6-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid
  • Figure US20240041837A1-20240208-C00046
    • Example 19: 3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-propoxy-[1,1′-biphenyl]-3-carboxylic acid
  • Figure US20240041837A1-20240208-C00047
    • Example 20: N-((3′-(3-(1-(4-(tert-Butyl)benzyl)4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-YI)propyl)-[1,1′-biphenyl]-3-yl)methyl)benzenesulfonamide
  • Figure US20240041837A1-20240208-C00048
  • Step 1: A mixture of 1-(4-(tert-butyl)benzyl)-4-ethyl-3-(3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1H-1,2,4-triazol-5(4H)-one (223 mg, 0.443 mmol), 3-bromobenzyl amine (98 mg, 0.532 mmol, 1.2 eq) and potassium carbonate (183 mg, 1.33 mmol, 3 eq) were taken up in DME (2 mL) and water (1 mL) solution. To this tetrakis(triphenylphosphine)palladium(0)(52 mg, 0.0443 mmol, 0.1 eq) was added and the resulting mixture was stirred at 85° C. under an atmosphere of N2 for 24 hr. The reaction mixture was cooled to room temperature and the solvent was removed under vacuum. The crude material was partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc (3×20 mL) and the organic layer was dried over anhydrous Na2SO4. The solvent was evaporated in vacuum to obtain the crude product. The crude product was purified on flash column chromatography (silica gel, 0-70% EtOAc, 10% Methanol, 2.5% trieythylamine/Hexanes) to afford a white solid (84 mg, 40% yield) LC-MS: 483 (M+H)*.
  • Step 2: A mixture of 3-(3-(3′-(aminomethyl)-[1,1′-biphenyl]-3-yl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (35 mg, 0.0726 mmol) and benzene sulfonylchloride (10 μL, 0.0798 mmol, 1.1 eq) was stirred in pyridine (1 mL) at room temperature for 24 hr. The mixture was poured onto dichloromethane (40 mL) and washed with saturated CuSO4, water, and brine. The combined organic layers were dried over anhydrous Na2SO4, filtered and evaporated under vacuum to obtain the crude product. The crude product was purified on reverse phase HPLC to afford a white foam (10 mg, 33%). LC-MS: 623 (M+H)+.
    • Example 21: 3-(3′-(3-(1-(4-(ter-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methoxy-[1,1′-biphenyl]-3-yl)propanoic acid
  • Figure US20240041837A1-20240208-C00049
  • A mixture of 1-(4-(tert-butyl)benzyl)-4-ethyl-3-(3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1H-1,2,4-triazol-5(4H)-one (70 mg, 0.139 mmol), 3-(5-bromo-2-methoxyphenyl) propanoic acid (43 mg, 0.167 mmol, 1.2 eq) and potassium phosphate tribasic (118 mg, 0.556 mmol, 4 eq) were taken up in DME (2 mL) and water (1 mL) solution. To this tris(dibenzylideneacetone)dipalladium(0) (4 mg, 0.0034 mmol, 0.025 eq) and 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (5 mg, 0.011 mmol, 0.08 eq) were added and the resulting mixture was stirred at 85° C. under an atmosphere of N2 for 24 hr. The reaction mixture was cooled to room temperature and the solvent was removed under vacuum. The crude material was partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc (3×20 mL) and the organic layer was dried over anhydrous Na2SO4. The solvent was evaporated in vacuum to obtain the crude product. The crude product was purified on reverse phase HPLC to afford a white solid (10 mg, 13% yield) LC-MS: 556 (M+H)+.
    • Example 22: 2-(3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1,1-difluoropropyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid
  • Figure US20240041837A1-20240208-C00050
  • Step 1: To a solution of 4-(3-bromophenyl)-4-oxobutanenitrile (1.11 g, 4.66 mmol) in toluene (10 mL) was added Deoxyfluor (8.63 mL, 23.31 mmol, 2.7 M solution in Toluene) followed by EOH (0.16 m L, 2.80 mmol). The mixture was stirred at 80° C. for 16 hrs. The solution was cooled to rt and diluted with diethyl ether and a solution of saturated aqueous NaHCO3. The organic layer was separated and washed sequentially with saturated aqueous NaHCO3, 1M aqueous HCl, and water. The organics were concentrated and residue was purified by column chromatography using 0%-65% gradient EtOAc/Hexanes as eluent to afford 0.570 g (47% yield) of 4-(3-bromophenyl)-4,4-difluorobutanenitrile.
  • Step 2:4-(3-Bromophenyl)-4,4-difluorobutanenitrile (0.57 g, 2.19 mmol), ethylene glycol (20 mL), water (2 mL), and KOH (0.701 g, 17.53 mmol) were combined and heated at 80° C. for 16 hrs. The solution was cooled to rt, diluted with EtOAc and quenched with 1M aqueous HCl. The organics were separated and washed sequentially with 0.1M aqueous HCl and brine, filtered through a Na2SO4/paper plug and concentrated. The organics were concentrated and residue was purified by column chromatography using 0%-50% gradient acetone/hexanes as eluent to afford 0.386 g (63% yield) of 4-(3-bromophenyl)-4,4-difluorobutanoic acid.
  • Step 3: 4-(3-Bromophenyl)-4,4-difluorobutanoic acid (0.20 g, 0.717 mmol), Hunig's base (0.33 mL, 1.86 mmol) and 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.327 g, 0.86 mmol) were combined in anhydrous DMF (7 mL). The reaction solution was stirred for 40 min at rt, then intermediate (M) (0.248 g, 0.717 mmol) was added. The resulting solution was allowed to stir at rt for 16 h. The reaction mixture was then diluted with EtOAc and 1 N aq. HCl. The organics were separated and washed sequentially with saturated aqueous NaHCO3, water, and brine. The organic extract was then dried over sodium sulfate and filtered. Concentration of the filtrate afforded crude 2-(4-(3-bromophenyl)-4,4-difluorobutanoyl)-1-(4-(tert-butyl)benzyl)-N-ethylhydrazinecarboxamide, which was used as is in the next step.
  • Step 4: To an EtOAc solution (8 mL) of 2-(4-(3-bromophenyl)-4,4-difluorobutanoyl)-1-(4-(tert-butyl)benzyl)-N-ethylhydrazinecarboxamide (0.365 g, 0.717 mmol) was added camphorsulfonic acid (0.18 g, 0.717 mmol) and the resulting solution was heated at reflux for 16 h. The reaction mixture was then diluted with EtOAc and 1 N aq. HCl. The organics were washed sequentially with 1M NaOH and water, and then concentrated. The residue was purified by column chromatography using 10%-90% gradient EtOAc/hexanes as eluent to afford 0.140 g (40% yield, two steps) of 3-(3-(3-bromophenyl)-3,3-difluoropropyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one.
  • Step 5: Under a nitrogen atmosphere, 3-(3-(3-bromophenyl)-3,3-difluoropropyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (0.040 g, 0.081 mmol) and methyl 2-(2-ethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate (0.029 g, 0.089 mmol) were dissolved in dioxane (3 mL) to which was then added a solution of saturated aqueous NaHCO3 (1 mL). The resulting solution was then subsurface purged with N2 for 5 minutes after which, Pd(PPh)4 (0.016 g, 0.014 mmol) was added. The resulting mixture was stirred in a sealed pressure vessel at 90° C. for 16 hrs. The solution was cooled to rt and diluted with EtOAc and water. The organics were washed once more with water and the solution was filtered through a Na2SO4/paper plug and concentrated. The residue was purified by preparatory TLC using 20% acetone/hexanes as eluent to afford 0.029 g of methyl 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1,1-difluoropropyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetate (59% yield).
  • Step 6: To a solution of methyl 2-(3′-(3-(1-(4-(tert-butyl)benzyl)4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1,1-difluoropropyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetate (0.029 g, 0.048 mmol) in THF (1 mL) and MeOH (1 mL) was added water (0.62 mL) and 1M aq. LiOH (0.38 mL, 0.37 mmol). The resulting mixture was then stirred at 35° C. for 48 hrs. The solvents were evaporated and the residue treated with EtOAc and a 20% aq. solution of citric acid. The organic layer was separated and extracted with water (2×). The organics were concentrated to afford 0.029 g (100% yield) of the title compound as a brown solid. LCMS (ESI), M+H 592.
    • Example 23: N-(6-(3-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1,1-difluoropropyl)phenyl)pyridin-3-yl)benzenesulfonamide
  • Figure US20240041837A1-20240208-C00051
  • Step 1: 3-(3-(3-Bromophenyl)-3,3-difluoropropyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (0.110 g, 0.223 mmol), bis(pinacolato)diborane (0.074 g, 0.290 mmol), KOAc (0.066 g, 0.669 mmol) were dissolved in dioxane (4 mL) and the resulting solution was subsurface purged with N2 for 5 minutes after which, Pd(dppf)Cl2 (0.016 g, 0.014 mmol) was added. The resulting mixture was stirred in a sealed pressure vessel at 85° C. for 16 hrs. The solution was cooled to rt and diluted with DCM and water. The organics were washed once more with water and the solution was filtered through a Na2SO4/paper plug and concentrated. The residue was purified by preparatory TLC using 40% EtOAc/hexanes as eluent to afford 0.065 g of 1-(4-(tert-butyl)benzyl)-3-(3,3-difluoro-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (54% yield).
  • Step 2: Under a nitrogen atmosphere, 1-(4-(tert-butyl)benzyl)-3-(3,3-difluoro-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (0.065 g, 0.120 mmol) from the previous step and N-(6-bromopyridin-3-yl)benzenesulfonamide (0.042 g, 0.133 mmol) were dissolved in dioxane (3 mL). To this solution was then added a solution of saturated aqueous NaHCO3 (1 mL) and the resulting biphasic mixture was then subsurface purged with N2 for 5 minutes. Finally. Pd(PPh)4 (0.014 g, 0.012 mmol) was added and the resulting mixture was stirred in a sealed pressure vessel at 85° C. for 16 hrs. The solution was cooled to rt, evaporated, and diluted with EtOAc and 1:1 brine/water. The organics were washed once more with water and brine. The organics were then filtered through a Na2SO4/paper plug and concentrated. The residue was purified by preparatory LCMS (C18 reverse phase) using 0% to 100% CH3CN/water as eluent to afford 0.013 g of the title compound (17% yield). LCMS (ESI), M+H 646.
    • Example 24: 2-(5-(6-(3-(1-(4-(ter-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyridin-2-yl)-2-methoxyethenyl)acetic acid
  • Figure US20240041837A1-20240208-C00052
  • Step 1: To a degassed (sparged) solution of 2-bromo-6-chloropyridine (2.0 g, 10.4 mmol) in THF (75 mL) was added Pd(PPh3)4 (200 mg) followed by a solution of (4-ethoxy-4-oxobutyl)zinc(II) bromide (0.5M in THF: 20.8 mL, 20.8 mmol). After stirring at room temperature for 2 hrs, the solution was poured on to a mixture of ice and 1N HCl, extracted with EtOAc, the organic phase separated, dried (MgSO4), filtered and evaporated. The isolated residue was purified on silica gel (0 to 30% EtOAc in hexanes) to afford 1.4 g of ethyl 4-(6-chloropyridin-2-yl)butanoate.
  • Step 2: Lithium hydroxide monohydrate (400 mg) was added to a solution of ethyl 4-(6-chloropyridin-2-yl)butanoate (1.4 g, 7.0 mmol) in a mixture of THF (20 mL), MeOH (8 mL) and water (8 mL). After stirring at room temperature for 1 hr, the solution was diluted with EtOAc and water. Sol id citric acid was then added until an acidic pH was attained and the organic phase separated, washed with water, dried (MgSO4), filtered and evaporated to afford 4-(6-chloropyridin-2-yl)butanoic acid. The crude product thus obtained was used without further purification.
  • Step 3: To a solution of 4-(6-chloropyridin-2-yl)butanoic acid (600 mg, 3.0 mmol) in DMF (15 mL) was added HATU (1.3 g, 3.42 mmol) followed by DIPEA (1.6 mL) and stirred at RT for 30 minutes. Intermediate (M) (1.2 g, 3.47 mmol) was then added and the solution allowed to stir at rt for 24 hrs. The reaction mixture was partitioned between EtOAc and water, the organic phase separated, dried (MgSO4) and filtered. To the filtrate was then added camphorsulfonic acid (697 mg, 3.0 mmol) and the resulting mixture was heated to reflux for 24 hrs. After cooling, the solution was neutralized following the addition of saturated aqueous NaHCO3. The organic phase was then separated, dried (MgSO4), filtered and evaporated in vacuo. The residue thus obtained was purified on silica gel, eluting with a gradient of 0 to 80% EtOAc in hexanes to afford 1-(4-(tert-butyl)benzyl)-3-(3-(6-chloropyridin-2-yl)propyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one.
  • Step 4: The title compound was then obtained as previously described for Example 1, whereby the requisite boronate was cross-coupled and the resulting ester was then hydrolyzed under the same conditions.
    • Example 25: 3-(3-(3′-(1H-Tetrazol-5-yl)-[1,1′-biphenyl]-3-yl)propyl)-1-(4-(ter-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one
  • Figure US20240041837A1-20240208-C00053
  • A mixture of 3-(3-(3′-bromo-[1,1′-biphenyl]-3-yl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one (112 mg, 0.245 mmol), 3-(tetrazol-5yl)phenylboronic acid (46 mg, 0.245 mmol, 1.0 eq) and potassium phosphate tribasic (208 mg, 0.980 mmol, 4 eq) were taken up in a DME (2 mL) and water (1 mL) solution. To this was added tris(dibenzylideneacetone)dipalladium(0) (6 mg, 0.0061 mmol, 0.025 eq) and 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (20 mg, 0.049 mmol, 0.2 eq), and the resulting mixture was stirred at 85° C. under an atmosphere of N2 for 24 hr. The reaction mixture was cooled to room temperature and the solvent was removed under vacuum. The crude material was then partitioned between water and EtOAc. The aqueous layer was separated and extracted further with EtOAc (3×20 mL). The combined organic extracts were dried over anhydrous Na2SO4. The solvent was evaporated in vacuum to obtain the crude product. The crude product was purified on reverse phase HPLC to afford a white solid (20 mg, 16% yield) LC-MS: 521 (M+H)*.
    • Example 26: 2-(5-(4-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyrimidin-2-yl)-2-ethoxyphenyl)acetic acid
  • Figure US20240041837A1-20240208-C00054
  • Step 1: To a THF solution of 2,4-dichloropyrimidine (1.00 g, 6.71 mmol) was added at 0° C. (4-ethoxy-4-oxobutyl)zinc(II) bromide (13.42 mL, 6.71 mmol, 0.5 M in THF) followed by Pd(PPh)4 (0.194 g, 0.167 mmol). The reaction mixture thus obtained was then allowed to slowly warm to rt. By TLC, it was noted that this reaction had stalled after 1.5 hr, so another spatula tip of Pd(PPh)4 was then added and reaction was allowed to continue at rt for another 16 hrs. The reaction mixture was then poured into ice-cold 0.5M aq. HCl solution and diluted with EtOAc and brine. The organics were separated, washed once more with water and then concentrated. The residue was purified by column chromatography using 0%-50% gradient EtOAc/hexanes as eluent to afford 0.930 g (60% yield) of ethyl 4-(2-chloropyrimidin-4-yl)butanoate.
  • Step 2: Under a nitrogen atmosphere, ethyl 4-(2-chloropyrimidin-4-yl)butanoate (0.193 g, 0.842 mmol) and ethyl 2-(2-ethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetonitrile (0.220 g, 0.766 mmol) were dissolved in dioxane (8 mL) to which was added a solution of saturated aqueous NaHCO3 (4 mL). The resulting solution was then subsurface purged with N2 for 5 minutes after which, Pd(PPh)4 (0.088 g, 0.077 mmol) was added. The resulting mixture was stirred in a sealed pressure vessel at 85° C. for 16 hrs. The solution was cooled to rt, evaporated, and diluted with EtOAc and brine. The aqueous laver was extracted twice more with DCM and the combined organics were concentrated. The residue was purified by column chromatography using 0%-60% gradient EtOAc/hexanes as eluent to afford 0.144 g (54% yield) of 4-(2-(3-(cyanomethyl)-4-ethoxyphenyl)pyrimidin-4-yl)butanoate.
  • Step 3: To a solution of ethyl 4-(2-(3-(cyanomethyl)4-ethoxyphenyl)pyrimidin-4-yl)butanoate (0.360 g, 1.02 mmol) in THF (8 mL) and MeOH (8 mL) was added 1M aq. LiOH (8.02 mL, 8.02 mmol). The resulting mixture was then stirred at rt for 1.5 hrs. The solvents were evaporated and the residue treated with EtOAc and a 20% aq. solution of citric acid. The organic layer was separated and washed with water (2×). The organics were then filtered through a Na2SO4/paper plug and concentrated. The resulting crude 4-(2-(3-(cyanomethyl)-4-ethoxyphenyl)pyrimidin-4-yl)butanoic acid thus obtained was used directly in the next step.
  • Step 4: 4-(2-(3-(Cyanomethyl)-4-ethoxyphenyl)pyrimidin-4-yl)butanoic acid (0.32 g, 0.984 mmol), Hunig's base (0.45 mL, 1.86 mmol) and 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.449 g, 1.18 mmol) were combined in anhydrous DMF (10 mL). The reaction solution was stirred for 40 min at rt before intermediate (M) (0.248 g, 0.717 mmol), dissolved in a minimal amount of DMF, was added dropwise. The resulting solution was allowed to stir at rt for 16 h. The reaction mixture was then evaporated and diluted with EtOAc and water. The organics were washed sequentially with saturated aqueous NaHCO3 and brine, dried over sodium sulfate, filtered and the filtrate concentrated. The crude 1-(4-(tert-butyl)benzyl)-2-(4-(2-(3-(cyanomethyl)-4-ethoxyphenyl)pyrimidin-4-yl)butanoyl)-N-ethylhydrazinecarboxamide thus obtained was used as is in the next step.
  • Step 5: To an EtOAc solution (10 mL) of 1-(4-(tert-butyl)benzyl)-2-(4-(2-(3-(cyanomethyl)-4-ethoxyphenyl)pyrimidin-4-yl)butanoyl)-N-ethylhydrazinecarboxamide (0.547 g, 0.982 mmol) was added camphorsulfonic acid (0.228 g, 0.982 mmol) and the resulting solution was heated at reflux for 16 h. The reaction mixture was then diluted with EtOAc and brine. The organics were separated and washed sequentially with 1M NaOH, water, and brine. The organic extract was then dried over sodium sulfate, filtered and the filtrate concentrated. The residue was purified by column chromatography using 0%-50% gradient acetone/hexanes as eluent to afford 0.300 g (57% yield, three steps) of 2-(5-(4-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyrimidin-2-yl)-2-ethoxyphenyl)acetonitrile.
  • Step 6: To a solution of 2-(5-(4-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyrimidin-2-yl)-2-ethoxyphenyl)acetonitrile (0.100 g, 0.186 mmol) in ethylene glycol (6 mL) and water (1.5 mL) was added 18M KOH (0.104 mL, 1.86 mmol). The resulting mixture was then stirred at 120° C. for 16 hrs. The reaction was quenched with 1 M aq. HCl (1.86 mL, 1.86 mmol) and the residue was diluted with EtOAc and water. The organic layer was separated and washed further with water (2×). The organics were then filtered through a Na2SO4/paper plug and concentrated. The organics were concentrated to afford 0.095 g (92% yield) of the title compound as a yellow solid. LCMS (ESI), M+H 558.
    • Example 27: 2-(5-(6-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyrimidin-4-yl)-2-ethoxyphenyl)acetic acid
  • Figure US20240041837A1-20240208-C00055
  • The title compound was prepared in an analogous fashion to Example 26 but using instead the requisite commercially available 4,6-dichloropyrimidine in the first step. LCMS (ESI), M+H 558.
    • Examples 28 (R=Me), 29 (R=Et) and 30 (R=nPr); (3′-(3-(1-(4-(tert-Butyl)benzyl)-4ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-alkoxy-[1,1′-biphenyl]-4-yl)acetic add
  • Figure US20240041837A1-20240208-C00056
    • Example 31: 2-(3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-hydroxy-[1,1′-biphenyl]-4-yl)acetic add
  • Figure US20240041837A1-20240208-C00057
  • Step 1: In a 75 mL screw-cap reaction flask equipped with a magnetic stirrer was combined 1-(4-(tert-butyl)benzyl)-4-ethyl-3-(3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1H-1,2,4-triazol-5(4H)-one (300 mg, 0.60 mmol), methyl 2-(benzyloxy)-5-bromobenzoate (200 mg, 0.60 mmol) and K3PO4 (330 mg, 2.4 mmol) in DME (4 mL) and water (2 mL). The resulting biphasic mixture was then subsurface purged with N2 for 15 min after which, Pd2(dba)3 (14 mg, 0.015 mmol) and 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (25 mg, 0.060 mmol) were added in one rapid portion. The now golden-yellow biphasic suspension was subsurface purged with N2 for another 15 min before the vessel was tightly sealed and then heated at 85° C. for 15 h. The now dark orange reaction suspension was allowed to cool to RT, diluted with tert-butyl methyl ether and washed sequentially with 10% aq. HCl, water and brine. The organic extract thus obtained was then dried over Na2SO4, de-colorized with activated charcoal and finally filtered through a pad of ether-wetted celite. The insolubles were rinsed further with tert-butyl methyl ether and the filtrate thus obtained was concentrated in vacuo. Purification of the crude product thus obtained by way of column chromatography (SiO2, gradient elution, 4:1 Hex:EtOAc→EtOAc) furnished 2-(3-(benzyloxy)-3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-yl)acetate as a pale yellow oil (190 mg, 49% yield).
  • Step 2: In a 500 mL Parr shaker flask was dissolved methyl 2-(3-(benzyloxy)-3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-yl)acetate (190 mg, 29 mmol) from the previous step in MeOH (10 mL). To this was then added Pd/C (10% wt/wt wet, 120 mg, 0.06 mmol) and the resulting suspension was thoroughly deoxygenated via subsurface purging with nitrogen. The reaction vessel was then connected to a Parr shaker and the reaction suspension was shaken under 50 psi of H2 for 5 h. The excess H2 was discharged from the vessel and the reaction was immediately quenched with DCM. The deactivated catalyst was then removed via filtration through a pad of DCM-wetted celite and the insolubles were washed thoroughly with DCM. The filtrate thus obtained was concentrated in vacuo to furnish a pale yellow solid. Purification of the crude product thus obtained by way of column chromatography (SiO2, gradient elution, 4:1 Hex:EtOAc 4 EtOAc) furnished methyl 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-hydroxy-[1,1′-biphenyl]-4-yl)acetate as a pale yellow solid (110 mg, 66% yield).
  • Step 3: In a 50 mL RBF equipped with a magnetic stirrer was added methyl 2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-hydroxy-[1,1′-biphenyl]-4-yl)acetate (35 mg, 0.065 mmol) from the previous step in THF (1 mL) and MeOH (0.5 mL). To this was then added 2N aq. LiOH (0.2 mL, 0.4 mmol) and the resulting solution was stirred at RT for 16 h. The volatiles were then removed in vacuo and the resulting residue was acidified with 1 N aq. HCl and extracted with DCM (3×10 mL). The combined organic extracts were then washed further with water and brine, dried over Na2SO4 and filtered. Concentration of the filtrate thus obtained in vacuo furnished the title compound as a white solid (33 mg, 66% yield). LC-MS: 528 (M+H)+, 526 (M−H)−.
    • Example 32: 2-(3′-(3-(1-(4(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-isopropoxy-[1,1′-biphenyl]-3-yl)acetic acid
  • Figure US20240041837A1-20240208-C00058
    • Example 33: 2-(3′-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-Oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-(2-(dimethylamino)ethoxy)-[1,1′-biphenyl]-3-yl)acetic add
  • Figure US20240041837A1-20240208-C00059
  • Human PPARα
    Reporter Assay -
    Luciferase IC50
    Example Structure (nM) MS(ESI)
    1
    Figure US20240041837A1-20240208-C00060
         		346 512 (M + H)
    2
    Figure US20240041837A1-20240208-C00061
         		324 512 (M + H)
    3
    Figure US20240041837A1-20240208-C00062
         		1333 498 (M + H)
    4
    Figure US20240041837A1-20240208-C00063
         		110 498 (M + H)
    5
    Figure US20240041837A1-20240208-C00064
         		137 582 (M + H)
    6
    Figure US20240041837A1-20240208-C00065
         		58 554 (M − H)
    7
    Figure US20240041837A1-20240208-C00066
         		77 538 (M + H)
    8
    Figure US20240041837A1-20240208-C00067
         		487 538 (M + H)
    9
    Figure US20240041837A1-20240208-C00068
         		548 528 (M + H)
    10
    Figure US20240041837A1-20240208-C00069
         		211 542 (M + H)
    11
    Figure US20240041837A1-20240208-C00070
         		48 570 (M + H)
    12
    Figure US20240041837A1-20240208-C00071
         		302 610 (M + H)
    13
    Figure US20240041837A1-20240208-C00072
         		197 542 (M + H)
    14
    Figure US20240041837A1-20240208-C00073
         		234 552 (M + H)
    15
    Figure US20240041837A1-20240208-C00074
         		122 618 (M + H)
    16
    Figure US20240041837A1-20240208-C00075
         		141 582 (M + H)
    17
    Figure US20240041837A1-20240208-C00076
         		83 530 (M + H)
    18
    Figure US20240041837A1-20240208-C00077
         		750 556 (M + H)
    19
    Figure US20240041837A1-20240208-C00078
         		119 556 (M + H)
    20
    Figure US20240041837A1-20240208-C00079
         		896 623 (M + H)
    21
    Figure US20240041837A1-20240208-C00080
         		610 556 (M + H)
    22
    Figure US20240041837A1-20240208-C00081
         		64 592 (M + H)
    23
    Figure US20240041837A1-20240208-C00082
         		659 646 (M + H)
    24
    Figure US20240041837A1-20240208-C00083
         		2531 543 (M + H)
    25
    Figure US20240041837A1-20240208-C00084
         		2293 521 (M + H)
    26
    Figure US20240041837A1-20240208-C00085
         		1238 558 (M + H)
    27
    Figure US20240041837A1-20240208-C00086
         		3431 558 (M + H)
    28
    Figure US20240041837A1-20240208-C00087
         		140 542 (M + H)
    29
    Figure US20240041837A1-20240208-C00088
         		59 556 (M + H)
    30
    Figure US20240041837A1-20240208-C00089
         		36 570 (M + H)
    31
    Figure US20240041837A1-20240208-C00090
         		528 (M + H)
    32
    Figure US20240041837A1-20240208-C00091
         		570 (M + H)
    33
    Figure US20240041837A1-20240208-C00092
         		599 (M + H)
  • While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims (23)

1.-32. (canceled)
33. A compound selected from the group consisting of:
Figure US20240041837A1-20240208-C00093
Figure US20240041837A1-20240208-C00094
or a pharmaceutically acceptable salt thereof.
34. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00095
or a pharmaceutically acceptable salt thereof.
35. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00096
or a pharmaceutically acceptable salt thereof.
36. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00097
or a pharmaceutically acceptable salt thereof.
37. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00098
or a pharmaceutically acceptable salt thereof.
38. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00099
or a pharmaceutically acceptable salt thereof.
39. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00100
or a pharmaceutically acceptable salt thereof.
40. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00101
or a pharmaceutically acceptable salt thereof.
41. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00102
or a pharmaceutically acceptable salt thereof.
42. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00103
or a pharmaceutically acceptable salt thereof.
43. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00104
or a pharmaceutically acceptable salt thereof.
44. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00105
or a pharmaceutically acceptable salt thereof.
45. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00106
or a pharmaceutically acceptable salt thereof.
46. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00107
or a pharmaceutically acceptable salt thereof.
47. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00108
or a pharmaceutically acceptable salt thereof.
48. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00109
or a pharmaceutically acceptable salt thereof.
49. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00110
or a pharmaceutically acceptable salt thereof.
50. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00111
or a pharmaceutically acceptable salt thereof.
51. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00112
or a pharmaceutically acceptable salt thereof.
52. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00113
or a pharmaceutically acceptable salt thereof.
53. The compound of claim 33, wherein the compound is:
Figure US20240041837A1-20240208-C00114
or a pharmaceutically acceptable salt thereof.
54. A pharmaceutical composition comprising the compound of claim 33, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
US18/304,815 2012-12-20 2023-04-21 Triazolone compounds and uses thereof Pending US20240041837A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/304,815 US20240041837A1 (en) 2012-12-20 2023-04-21 Triazolone compounds and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261739906P 2012-12-20 2012-12-20
PCT/US2013/074197 WO2014099503A1 (en) 2012-12-20 2013-12-10 Triazolone compounds and uses thereof
US201514654225A 2015-06-19 2015-06-19
US15/590,766 US10568871B2 (en) 2012-12-20 2017-05-09 Triazolone compounds and uses thereof
US16/722,773 US11666557B2 (en) 2012-12-20 2019-12-20 Triazolone compounds and uses thereof
US18/304,815 US20240041837A1 (en) 2012-12-20 2023-04-21 Triazolone compounds and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/722,773 Continuation US11666557B2 (en) 2012-12-20 2019-12-20 Triazolone compounds and uses thereof

Publications (1)

Publication Number Publication Date
US20240041837A1 true US20240041837A1 (en) 2024-02-08

Family

ID=50979036

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/654,225 Active US9676754B2 (en) 2012-12-20 2013-12-10 Triazolone compounds and uses thereof
US15/590,766 Active US10568871B2 (en) 2012-12-20 2017-05-09 Triazolone compounds and uses thereof
US16/722,773 Active 2034-09-29 US11666557B2 (en) 2012-12-20 2019-12-20 Triazolone compounds and uses thereof
US18/304,815 Pending US20240041837A1 (en) 2012-12-20 2023-04-21 Triazolone compounds and uses thereof

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US14/654,225 Active US9676754B2 (en) 2012-12-20 2013-12-10 Triazolone compounds and uses thereof
US15/590,766 Active US10568871B2 (en) 2012-12-20 2017-05-09 Triazolone compounds and uses thereof
US16/722,773 Active 2034-09-29 US11666557B2 (en) 2012-12-20 2019-12-20 Triazolone compounds and uses thereof

Country Status (18)

Country Link
US (4) US9676754B2 (en)
EP (1) EP2935228B9 (en)
JP (1) JP6404230B2 (en)
KR (1) KR102300675B1 (en)
CN (1) CN104918922B (en)
AU (1) AU2013363398B2 (en)
BR (1) BR112015013350B1 (en)
CA (1) CA2894281C (en)
DK (1) DK2935228T3 (en)
EA (1) EA027986B9 (en)
ES (1) ES2660249T3 (en)
HK (1) HK1212680A1 (en)
IL (1) IL239372B (en)
MX (1) MX2015007433A (en)
NO (1) NO3003327T3 (en)
PE (1) PE20151521A1 (en)
SG (1) SG11201504622PA (en)
WO (1) WO2014099503A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014099503A1 (en) 2012-12-20 2014-06-26 Inception 2, Inc. Triazolone compounds and uses thereof
KR20160048988A (en) 2013-09-06 2016-05-04 인셉션 2 인코퍼레이티드 Triazolone compounds and uses thereof
CN116367861A (en) * 2020-09-14 2023-06-30 上海弼领生物技术有限公司 Application of PPARα (peroxisome proliferator-activated receptor α) ligand in preparation of medicines

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE160447C (en)
NL189197C (en) 1979-09-04 1993-02-01 Bristol Myers Squibb Co 3,4-SUBSTITUTED-1,2,5-THIADIAZOLO-1-OXIDES AND 1,1-DIOXIDES, PREPARATION THEREOF, AND PHARMACEUTICAL PREPARATIONS.
US4487773A (en) 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
IN158869B (en) 1981-03-18 1987-02-07 Ici Plc
DD160447A1 (en) 1981-03-26 1983-08-03 Johannes Dost HERBICIDAL AGENTS CONTAINING 1,2,4-TRIAZOLINONE- (5)
EP0067508B1 (en) 1981-05-18 1985-10-30 Imperial Chemical Industries Plc Amidine derivatives
DE3238590A1 (en) 1982-10-19 1984-04-19 VEB Fahlberg-List Chemische und pharmazeutische Fabriken, DDR 3013 Magdeburg Herbicidal agent comprising 1,2,4-triazolin-5-ones
NL8204109A (en) 1982-10-25 1984-05-16 Fahlberg List Veb 1,2,4-Triazoline-5-one herbicides for galium species - give good control of resistant weeds in cereal and sugar beet e.g. the 3-benzyl-4-para methoxyphenyl cpd.
BE894856A (en) 1982-10-28 1983-02-14 Fahlberg List Veb 1,2,4-Triazoline-5-one herbicides for galium species - give good control of resistant weeds in cereal and sugar beet e.g. the 3-benzyl-4-para methoxyphenyl cpd.
FR2535168B1 (en) 1982-10-29 1985-08-09 Fahlberg List Veb HERBICIDE AGENTS BASED ON 1, 2, 4-TRIAZOLINONE 5
JPS60215675A (en) 1984-04-09 1985-10-29 Nippon Nohyaku Co Ltd Oxadiazolinone derivative and triazolinone derivative, their preparation, and agent for controlling growth of insect
PH24094A (en) 1986-12-19 1990-03-05 Merrell Dow Pharma 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
DE3934081A1 (en) 1989-10-12 1991-04-18 Bayer Ag SULFONYLAMINOCARBONYLTRIAZOLINONE
WO1992004346A1 (en) 1990-09-06 1992-03-19 Pfizer Limited Antimuscarinic bronchodilators
JP2772875B2 (en) 1991-05-14 1998-07-09 富士写真フイルム株式会社 Processing method of silver halide color photographic light-sensitive material and photographic bleach-fixing composition
DE69230498T2 (en) 1991-10-30 2000-07-27 Astra Ab Soedertaelje 2-pyrazinylethylamine derivatives and their use as medicines.
AU675786B2 (en) 1992-04-15 1997-02-20 Merck Sharp & Dohme Limited Azacyclic compounds
DE4224929A1 (en) 1992-07-28 1994-02-03 Bayer Ag Heterocyclyltriazolinones
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
IT1256387B (en) 1992-11-13 1995-12-04 Acraf PROCEDURE FOR PREPARING TRIAZOLONI
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
DE4343595A1 (en) 1993-12-21 1995-06-22 Bayer Ag Process for the preparation of sulfonylaminocarbonyltriazolinones
US5550118A (en) 1994-01-31 1996-08-27 Eli Lilly And Company Polyhydronorharman synthase inhibitors
DE4404848A1 (en) 1994-02-16 1995-08-17 Hoechst Ag Substituted cyclohexanol esters, their use for the treatment of diseases and pharmaceutical preparations
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
GB9418545D0 (en) 1994-09-15 1994-11-02 Merck Sharp & Dohme Therapeutic agents
JPH08157473A (en) 1994-10-06 1996-06-18 Nissan Chem Ind Ltd Pyrazole-based thiazolidines
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
IN183333B (en) 1995-03-15 1999-11-20 Indian Drugs & Pharma
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
DE19521162A1 (en) 1995-06-09 1996-12-12 Bayer Ag N-aryl-1,2,4-triazolin-5-one
GB9513117D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9513121D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
DE19601189A1 (en) 1996-01-15 1997-07-17 Degussa High yield and economical preparation of 1,2,4-tri:azolin-3(2H)-one(s)
EP0784053A1 (en) 1996-01-15 1997-07-16 Degussa Aktiengesellschaft Process for the preparation of triazolinone herbicides
JP2000511883A (en) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ Modulators of molecules with phosphotyrosine recognition units
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
EP0929303B1 (en) 1996-10-07 2006-07-26 Merck Sharp & Dohme Ltd. Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
ATE314097T1 (en) 1996-10-28 2006-01-15 Amersham Health As CONTRAST AGENTS
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
AU8242598A (en) 1997-07-18 1999-02-10 Nippon Kayaku Kabushiki Kaisha Aromatic ketone derivatives and uses thereof
WO1999026945A1 (en) 1997-11-26 1999-06-03 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS
PL345110A1 (en) 1998-06-03 2001-12-03 Gpi Nil Holdings Aza-heterocyclic compounds used to treat neurological disorders and hair loss
SK18302000A3 (en) 1998-06-03 2001-06-11 Gpi Nil Holdings, Inc. N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
JP2002522494A (en) 1998-08-14 2002-07-23 ジーピーアイ エヌアイエル ホールディングス， インコーポレイテッド N-heterocyclic carboxylic acids and isosteric ureas and carbamates for visual and memory disorders
SE9802937D0 (en) * 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
AU1345600A (en) 1998-11-12 2000-06-05 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
FR2793791B1 (en) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot NOVEL INHIBITOR COMPOUNDS SPECIFIC TO A2 PHOSPHOLIPASES
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
DE19955662B4 (en) 1999-11-19 2011-03-31 Arysta LifeScience North America, Herbicides based on carbamoyltriazolinone
EP1110958A1 (en) 1999-12-20 2001-06-27 Ucb, S.A. Alpha-arylethylpiperazine derivatives as neurokinin antagonists
WO2001090102A2 (en) 2000-05-24 2001-11-29 Bayer Aktiengesellschaft 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
US6465456B2 (en) 2000-06-29 2002-10-15 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Polyarylcarboxamides useful as lipid lowering agents
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
UA82048C2 (en) * 2000-11-10 2008-03-11 Эли Лилли Энд Компани Peroxisome proliferator activated receptor alpha agonists
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
CA2469821C (en) 2001-12-18 2009-10-20 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
AU2003210916B9 (en) 2002-02-07 2008-12-18 The Curators Of The University Of Missouri Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
US20050256003A1 (en) 2002-06-14 2005-11-17 Christoph Luthy Novel herbicides
AU2003284001A1 (en) * 2002-10-07 2004-05-04 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
EP1558589A4 (en) 2002-10-11 2008-01-09 Cytokinetics Inc Compounds, compositions, and methods
KR20050075356A (en) 2002-10-11 2005-07-20 싸이토키네틱스, 인코포레이티드 Compounds, compositions, and methods
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
CA2521396A1 (en) 2003-04-04 2004-10-21 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
ATE455547T1 (en) 2003-04-11 2010-02-15 High Point Pharmaceuticals Llc PHARMACEUTICAL USES OF CONDENSED 1,2,4-TRIAZOLES
UA89035C2 (en) 2003-12-03 2009-12-25 Лео Фарма А/С Hydroxamic acid esters and pharmaceutical use thereof
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077178A2 (en) 2004-02-16 2005-08-25 Syngenta Participations Ag Herbicidal composition
EP1720860A1 (en) 2004-02-18 2006-11-15 AstraZeneca AB Triazole compounds and their use as metabotropic glutamate receptor antagonists
SE0400850D0 (en) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
ES2391461T3 (en) * 2004-07-27 2012-11-27 F. Hoffmann-La Roche Ag Benzyltriazolone compounds used as non-nucleoside reverse transcriptase inhibitors
CN1315810C (en) 2004-08-30 2007-05-16 北京理工大学 Piperazine-bridged tacrine binary derivatives and synthesis method thereof
HN2005000795A (en) 2004-10-15 2010-08-19 Aventis Pharma Inc PYRIMIDINS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR
CA2583681A1 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
WO2006068199A1 (en) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. Metabolically stable 3-oxy-1,2,4-triazole derivatives
JP5190270B2 (en) 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pyrazolopyrimidines as cell cycle kinase inhibitors
WO2006078698A1 (en) 2005-01-19 2006-07-27 Cengent Therapeutics, Inc. 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases
TW200640453A (en) 2005-01-28 2006-12-01 Lilly Co Eli Formulations and dosing regimen for PPAR-α modulators
EP1869024B1 (en) 2005-04-12 2010-11-10 Vicore Pharma AB New tricyclic angiotensin ii agonists
US7816822B2 (en) 2005-04-28 2010-10-19 Denso Corporation Motor and control unit thereof
DE102005025992A1 (en) 2005-06-07 2007-01-11 Lanxess Deutschland Gmbh Process for the preparation of substituted azoles
WO2007019397A2 (en) 2005-08-05 2007-02-15 Genelabs Technologies, Inc. 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus
CA2627497C (en) 2005-10-28 2014-10-14 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
NZ568666A (en) 2005-11-30 2011-09-30 Vertex Pharma [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met
DE102006003444A1 (en) 2006-01-25 2007-07-26 Lanxess Deutschland Gmbh Method for iodinating substituted azole compound and acid addition compound by converting substituted 1H-triazoles compound, with an oxidizing agent and elementary iodine and/or iodine compound in presence of a solvent or its mixture
GB2435828A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted phenyl-piperazine compounds for treatment of food related disorders
GB2435827A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted piperazine compounds for the treatment of food related disorders
GB2435829A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Pyrimidinyl-2-piperazine compounds for use in disorders related to food intake
EP1834953A1 (en) 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
MY148430A (en) 2006-03-23 2013-04-30 Biota Scient Management Antibacterial agents
CA2647423C (en) 2006-03-24 2015-02-17 Eisai R&D Management Co., Ltd. Triazolone derivative
DE102006023337A1 (en) * 2006-05-18 2007-11-22 Merck Patent Gmbh Triazole derivatives II
JP5441690B2 (en) * 2006-05-25 2014-03-12 シンタ ファーマシューティカルズ コーポレーション Triazole compounds that modulate Hsp90 activity
DE102006032164A1 (en) 2006-07-12 2008-01-24 Bayer Cropscience Ag Substituted furyl-sulfonylamino (thio) carbonyl-triazoline (thi) one
US7994321B2 (en) 2006-08-08 2011-08-09 Hoffmann-La Roche Inc. Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives
WO2008127349A2 (en) 2006-08-15 2008-10-23 Novartis Ag Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
JP2010519308A (en) 2007-02-23 2010-06-03 イーライ リリー アンド カンパニー Peroxisome proliferator-activated receptor modifier
BRPI0809617A2 (en) 2007-03-29 2014-09-16 Hoffmann La Roche NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
WO2008128335A1 (en) 2007-04-20 2008-10-30 Merck Frosst Canada Ltd. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2009017863A2 (en) 2007-05-08 2009-02-05 Burnham Institute For Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
CN101801942B (en) 2007-07-17 2013-03-27 美国艾森生物科学公司 Heterocyclic compounds and uses as anticancer agents
US8183381B2 (en) 2007-07-19 2012-05-22 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
JP5358571B2 (en) 2007-08-07 2013-12-04 プロサリク リミテッド 1,2,4-triazole derivatives as serotonergic regulators
JP5497650B2 (en) 2007-10-19 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング CCR10 antagonist
KR20100091255A (en) 2007-12-10 2010-08-18 7티엠 파마 에이/에스 Cannabinoid receptor modulators
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
MY156381A (en) 2008-05-14 2016-02-15 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
ES2423793T3 (en) 2008-05-26 2013-09-24 Genfit PPAR agonist compounds, preparation and uses for the treatment of diabetes and / or dyslipidemias
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US7943796B2 (en) * 2008-07-31 2011-05-17 Chevron Oronise Company LLC Lubricating oil additive and lubricating oil composition containing same
CN101643451B (en) 2008-08-07 2013-03-06 浙江海正药业股份有限公司 Peroxisome proliferator-activated receptor subtype delta agonist compound and preparation method thereof
JP2011231015A (en) 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk Novel uracil compound having nitrogenated heterocyclic ring or salt thereof
MX2011004125A (en) 2008-10-21 2011-05-19 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof.
KR101220182B1 (en) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 Azole derivatives, composition comprising thereof and method for treating parkinson's disease using the compounmd
US8883827B2 (en) 2009-06-05 2014-11-11 Oslo University Hospital Hf Azole derivatives as WTN pathway inhibitors
US20100331397A1 (en) 2009-06-24 2010-12-30 Alios Biopharma, Inc. 2-5a analogs and their methods of use
DE102009028929A1 (en) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use
WO2011058478A1 (en) 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
KR101169359B1 (en) 2010-01-29 2012-07-30 주식회사 레고켐 바이오사이언스 Novel Oxazolidinone derivatives with cyclic amidrazone and Pharmaceutical Compositions thereof
BR112012020976A2 (en) 2010-02-22 2017-05-09 Glaxosmithkline Llc triazolones as fatty acid synthase inhibitors
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
EP2560966B1 (en) 2010-03-30 2021-01-06 Verseon International Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
EP2371823A1 (en) 2010-04-01 2011-10-05 Bayer CropScience AG Cyclopropyl-substituted phenylsulfonylamino(thio)carbonyltriazolinones, their production and use as herbicides and plant growth regulators
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
ES2789177T3 (en) 2010-08-10 2020-10-26 Melinta Therapeutics Inc Cyclic boronic acid ester derivatives, process for their preparation and therapeutic uses thereof
US20130158063A1 (en) 2010-08-24 2013-06-20 Georgetown University Compounds, Compositions and Methods Related to PPAR Antagonists
EP2616071A2 (en) * 2010-09-17 2013-07-24 GlaxoSmithKline Intellectual Property Development Limited Fatty acid synthase inhibitors
JP5847533B2 (en) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 Novel thyroid hormone beta receptor agonist
WO2012058531A2 (en) 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
WO2014099503A1 (en) 2012-12-20 2014-06-26 Inception 2, Inc. Triazolone compounds and uses thereof
KR20160048988A (en) 2013-09-06 2016-05-04 인셉션 2 인코퍼레이티드 Triazolone compounds and uses thereof

Also Published As

Publication number Publication date
KR102300675B1 (en) 2021-09-13
EA201590909A1 (en) 2015-12-30
CN104918922A (en) 2015-09-16
EP2935228B1 (en) 2017-08-02
HK1212680A1 (en) 2016-06-17
JP6404230B2 (en) 2018-10-10
DK2935228T3 (en) 2017-10-30
BR112015013350B1 (en) 2022-04-05
PE20151521A1 (en) 2015-11-25
US20170239223A1 (en) 2017-08-24
MX2015007433A (en) 2015-12-07
US9676754B2 (en) 2017-06-13
US10568871B2 (en) 2020-02-25
WO2014099503A1 (en) 2014-06-26
AU2013363398A1 (en) 2015-07-23
EP2935228A4 (en) 2016-05-04
EP2935228A1 (en) 2015-10-28
US11666557B2 (en) 2023-06-06
EA027986B9 (en) 2018-01-31
CN104918922B (en) 2017-04-26
JP2016508132A (en) 2016-03-17
IL239372A0 (en) 2015-07-30
SG11201504622PA (en) 2015-07-30
EA027986B1 (en) 2017-09-29
NO3003327T3 (en) 2018-01-06
US20200138790A1 (en) 2020-05-07
AU2013363398B2 (en) 2017-06-01
ES2660249T3 (en) 2018-03-21
BR112015013350A2 (en) 2017-07-11
EP2935228B9 (en) 2017-12-06
KR20150099537A (en) 2015-08-31
CA2894281A1 (en) 2014-06-26
US20150344446A1 (en) 2015-12-03
CA2894281C (en) 2021-04-20
IL239372B (en) 2018-08-30

Similar Documents

Publication Publication Date Title
US9776976B2 (en) Triazolone compounds and uses thereof
US20240041837A1 (en) Triazolone compounds and uses thereof
US9505728B2 (en) Triazolone compounds and uses thereof
US9862708B2 (en) Pyrazolone compounds and uses thereof
US20240067660A1 (en) Macrocyclic spirocycle derivatives as mcl-1 inhibitors
EA021067B1 (en) Benzothiazolone derivatives
US20230021562A1 (en) Macrocylic indole derivatives mcl-1 inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: INCEPTION SCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STOCK, NICHOLAS SIMON;CHEN, AUSTIN CHIH-YU;BRAVO, YALDA MOSTOFI;AND OTHERS;SIGNING DATES FROM 20131213 TO 20140106;REEL/FRAME:063403/0116

Owner name: INCEPTION 2, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INCEPTION SCIENCES, INC.;REEL/FRAME:063403/0220

Effective date: 20140130

Owner name: TEMPEST THERAPEUTICS, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:INCEPTION 2, INC.;REEL/FRAME:063409/0342

Effective date: 20170814